{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:37:40Z","timestamp":1793230660391,"version":"4.5.0"},"reference-count":382,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01769-0","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:34:25Z","timestamp":1764318865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases"],"prefix":"10.1186","volume":"19","author":[{"given":"Xiaomei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peilong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"1769_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01952-8","author":"Y Song","year":"2024","unstructured":"Song Y, Li J, Wu Y. Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. Signal Transduct Target Ther. 2024. https:\/\/doi.org\/10.1038\/s41392-024-01952-8.","journal-title":"Signal Transduct Target Ther"},{"issue":"9894","key":"1769_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","volume":"382","author":"M Wahren-Herlenius","year":"2013","unstructured":"Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382(9894):819\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(13)60954-X.","journal-title":"Lancet"},{"issue":"7","key":"1769_CR3","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/jth.15313","volume":"19","author":"X Liu","year":"2021","unstructured":"Liu X, Arfman T, Wichapong K, Reutelingsperger CPM, Voorberg J, Nicolaes GAF. PAD4 takes charge during neutrophil activation: impact of PAD4 mediated NET formation on immune-mediated disease. J Thromb Haemost. 2021;19(7):1607\u201317. https:\/\/doi.org\/10.1111\/jth.15313.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"1769_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","volume":"19","author":"DS Pisetsky","year":"2023","unstructured":"Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023;19(8):509\u201324. https:\/\/doi.org\/10.1038\/s41581-023-00720-1.","journal-title":"Nat Rev Nephrol"},{"key":"1769_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1080310","volume":"14","author":"S Yang","year":"2023","unstructured":"Yang S, Zhao M, Jia S. Macrophage: key player in the pathogenesis of autoimmune diseases. Front Immunol. 2023;14:1080310. https:\/\/doi.org\/10.3389\/fimmu.2023.1080310.","journal-title":"Front Immunol"},{"issue":"2","key":"1769_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102743","volume":"20","author":"ZX Xiao","year":"2021","unstructured":"Xiao ZX, Miller JS, Zheng SG. An updated advance of autoantibodies in autoimmune diseases. Autoimmun Rev. 2021;20(2):102743. https:\/\/doi.org\/10.1016\/j.autrev.2020.102743.","journal-title":"Autoimmun Rev"},{"key":"1769_CR7","doi-asserted-by":"publisher","unstructured":"Abbas AK, Trotta E, Marson DRS, Bluestone A, Revisiting JA. IL-2: biology and therapeutic prospects. Sci Immunol. 2018;3(25). https:\/\/doi.org\/10.1126\/sciimmunol.aat1482. e-pub ahead of print 2018\/07\/08.","DOI":"10.1126\/sciimmunol.aat1482"},{"key":"1769_CR8","doi-asserted-by":"publisher","unstructured":"Kjorholt KE, Sundlisaeter NP, Aga AB, Sexton J, Olsen IC, Fremstad H et al. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial. Lancet Rheumatol 2024; 6(5): e268-e278. e-pub ahead of print 2024\/04\/08; https:\/\/doi.org\/10.1016\/S2665-9913(24)00021-3","DOI":"10.1016\/S2665-9913(24)00021-3"},{"issue":"1","key":"1769_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-020-00652-z","volume":"27","author":"WW Lin","year":"2020","unstructured":"Lin WW, Lu YC, Chuang CH, Cheng TL. Ab locks for improving the selectivity and safety of antibody drugs. J Biomed Sci. 2020;27(1):76. https:\/\/doi.org\/10.1186\/s12929-020-00652-z.","journal-title":"J Biomed Sci"},{"issue":"1","key":"1769_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0572-x","volume":"11","author":"J Weng","year":"2018","unstructured":"Weng J, Lai P, Qin L, Lai Y, Jiang Z, Luo C, et al. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol. 2018;11(1):25. https:\/\/doi.org\/10.1186\/s13045-018-0572-x.","journal-title":"J Hematol Oncol"},{"issue":"10297","key":"1769_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"key":"1769_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01308-1","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022. https:\/\/doi.org\/10.1186\/s13045-022-01308-1.","journal-title":"J Hematol Oncol"},{"issue":"7926","key":"1769_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609(7926):369\u201374. https:\/\/doi.org\/10.1038\/s41586-022-05140-y. e-pub ahead of print 2022\/09\/01.","journal-title":"Nature"},{"issue":"30","key":"1769_CR14","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.21.00917","volume":"39","author":"C Roddie","year":"2021","unstructured":"Roddie C, Dias J, O\u2019Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, et al. Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. J Clin Oncol. 2021;39(30):3352\u201363. https:\/\/doi.org\/10.1200\/JCO.21.00917.","journal-title":"J Clin Oncol"},{"key":"1769_CR15","doi-asserted-by":"publisher","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 2024; 187(18): 4890\u20134904 e4899. e-pub ahead of print 2024\/07\/17; https:\/\/doi.org\/10.1016\/j.cell.2024.06.027","DOI":"10.1016\/j.cell.2024.06.027"},{"key":"1769_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0819-1","author":"D Liu","year":"2019","unstructured":"Liu D. CAR-T \u201cthe living drugs\u201d, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol Oncol. 2019. https:\/\/doi.org\/10.1186\/s13045-019-0819-1.","journal-title":"J Hematol Oncol"},{"key":"1769_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.2132","author":"P Garantziotis","year":"2025","unstructured":"Garantziotis P, Beretta L, Lindblom J, Moysidou G-S, Nikolopoulos D, Grieshaber-Bouyer R, et al. Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus. Ann Rheum Dis. 2025. https:\/\/doi.org\/10.1016\/j.ard.2025.06.2132.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1769_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103648","volume":"23","author":"L Arnaud","year":"2024","unstructured":"Arnaud L, Chasset F, Martin T. Immunopathogenesis of systemic lupus erythematosus: an update. Autoimmun Rev. 2024;23(10):103648. https:\/\/doi.org\/10.1016\/j.autrev.2024.103648.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"1769_CR19","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1007\/s11427-021-2187-3","volume":"66","author":"X Chi","year":"2023","unstructured":"Chi X, Huang M, Tu H, Zhang B, Lin X, Xu H, et al. Innate and adaptive immune abnormalities underlying autoimmune diseases: the genetic connections. Sci China Life Sci. 2023;66(7):1482\u2013517. https:\/\/doi.org\/10.1007\/s11427-021-2187-3. e-pub ahead of print 2023\/02\/05.","journal-title":"Sci China Life Sci"},{"issue":"9","key":"1769_CR20","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","volume":"187","author":"H Chi","year":"2024","unstructured":"Chi H, Pepper M, Thomas PG. Principles and therapeutic applications of adaptive immunity. Cell. 2024;187(9):2052\u201378. https:\/\/doi.org\/10.1016\/j.cell.2024.03.037. e-pub ahead of print 2024\/04\/27.","journal-title":"Cell"},{"key":"1769_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109746","author":"X Chen","year":"2023","unstructured":"Chen X, Wang Y, Huang X, Geng S, Li C, Zeng L. Targeting bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice. Int Immunopharmacol. 2023. https:\/\/doi.org\/10.1016\/j.intimp.2023.109746.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"1769_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00401-022-02438-z","volume":"144","author":"C Preu\u00dfe","year":"2022","unstructured":"Preu\u00dfe C, Paesler B, Nelke C, Cengiz D, M\u00fcntefering T, Roos A, et al. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathol. 2022;144(2):353\u201372. https:\/\/doi.org\/10.1007\/s00401-022-02438-z.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"1769_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179\u201399. https:\/\/doi.org\/10.1038\/s41573-020-00092-2. e-pub ahead of print 2020\/12\/17.","journal-title":"Nat Rev Drug Discov"},{"key":"1769_CR24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.celrep.2018.06.074","volume":"24","author":"KJ Kenderes","year":"2018","unstructured":"Kenderes KJ, Levack RC, Papillion AM, Cabrera-Martinez B, Dishaw LM, Winslow GM. T-Bet\u2009+\u2009IgM memory cells generate multi-lineage effector B cells. Cell Rep. 2018;24:824-837.e823. https:\/\/doi.org\/10.1016\/j.celrep.2018.06.074.","journal-title":"Cell Rep"},{"key":"1769_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13440","author":"GM Winslow","year":"2025","unstructured":"Winslow GM, Levack R. Know Your ABCs: discovery, differentiation, and targeting of T-Bet\u2009+\u2009B cells. Immunol Rev. 2025. https:\/\/doi.org\/10.1111\/imr.13440.","journal-title":"Immunol Rev"},{"issue":"2","key":"1769_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102736","volume":"20","author":"T Mockel","year":"2021","unstructured":"Mockel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. 2021;20(2):102736. https:\/\/doi.org\/10.1016\/j.autrev.2020.102736.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1769_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41584-019-0211-0","volume":"15","author":"SJS Rubin","year":"2019","unstructured":"Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019;15(5):303\u201315. https:\/\/doi.org\/10.1038\/s41584-019-0211-0. e-pub ahead of print 2019\/04\/11.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1769_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jid.2021.05.038","volume":"142","author":"VD Dang","year":"2022","unstructured":"Dang VD, Stefanski AL, Lino AC, Dorner T. B- and plasma cell subsets in autoimmune diseases: translational perspectives. J Invest Dermatol. 2022;142(3):811\u201322. https:\/\/doi.org\/10.1016\/j.jid.2021.05.038.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1769_CR29","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","volume":"97","author":"E Crickx","year":"2020","unstructured":"Crickx E, Weill J-C, Reynaud C-A, Mah\u00e9vas M. Anti-CD20\u2013mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney Int. 2020;97(5):885\u201393. https:\/\/doi.org\/10.1016\/j.kint.2019.12.025.","journal-title":"Kidney Int"},{"issue":"6","key":"1769_CR30","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jaci.2022.10.035","volume":"151","author":"J Koers","year":"2023","unstructured":"Koers J, Sciarrillo R, Derksen NIL, Vletter EM, Filli\u00e9-Grijpma YE, Raveling-Eelsing E, et al. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. J Allergy Clin Immunol. 2023;151(6):1646\u201354. https:\/\/doi.org\/10.1016\/j.jaci.2022.10.035.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1769_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","volume":"17","author":"S Fillatreau","year":"2020","unstructured":"Fillatreau S, Manfroi B, D\u00f6rner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol. 2020;17(2):98\u2013108. https:\/\/doi.org\/10.1038\/s41584-020-00544-4.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"1769_CR32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/art.38307","volume":"66","author":"J Sokolove","year":"2014","unstructured":"Sokolove J, Johnson DS, Lahey LJ, Wagner CA, Cheng D, Thiele GM, et al. Rheumatoid factor as a potentiator of anti\u2013citrullinated protein antibody\u2013mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 2014;66(4):813\u201321. https:\/\/doi.org\/10.1002\/art.38307.","journal-title":"Arthritis Rheumatol"},{"issue":"20","key":"1769_CR33","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1093\/bioinformatics\/btv359","volume":"31","author":"NT Gupta","year":"2015","unstructured":"Gupta NT, Vander Heiden JA, Uduman M, Gadala-Maria D, Yaari G, Kleinstein SH. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics. 2015;31(20):3356\u20138. https:\/\/doi.org\/10.1093\/bioinformatics\/btv359.","journal-title":"Bioinformatics"},{"issue":"7","key":"1769_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nri.2017.24","volume":"17","author":"DJ Rawlings","year":"2017","unstructured":"Rawlings DJ, Metzler G, Wray-Dutra M, Jackson SW. Altered B cell signalling in autoimmunity. Nat Rev Immunol. 2017;17(7):421\u201336. https:\/\/doi.org\/10.1038\/nri.2017.24.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1769_CR35","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.immuni.2018.03.027","volume":"48","author":"W Ise","year":"2018","unstructured":"Ise W, Fujii K, Shiroguchi K, Ito A, Kometani K, Takeda K, et al. T follicular helper cell-Germinal center B cell interaction strength regulates entry into plasma cell or recycling germinal center cell fate. Immunity. 2018;48(4):702\u2013e715704. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.027.","journal-title":"Immunity"},{"issue":"7639","key":"1769_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature20810","volume":"542","author":"DA Rao","year":"2017","unstructured":"Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542(7639):110\u20134. https:\/\/doi.org\/10.1038\/nature20810.","journal-title":"Nature"},{"key":"1769_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49186-0","author":"G Dunlap","year":"2024","unstructured":"Dunlap G, Wagner A, Meednu N, Wang R, Zhang F, Ekabe JC. Clonal associations between lymphocyte subsets and functional states in rheumatoid arthritis synovium. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-49186-0.","journal-title":"Nat Commun"},{"key":"1769_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130062","author":"AV Bocharnikov","year":"2019","unstructured":"Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G. PD-1hiCXCR5\u2013 T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.130062.","journal-title":"JCI Insight"},{"issue":"1","key":"1769_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/art.40682","volume":"71","author":"MP Karampetsou","year":"2018","unstructured":"Karampetsou MP, Comte D, Su\u00e1rez-Fueyo A, Katsuyama E, Yoshida N, Kono M, et al. Signaling lymphocytic activation molecule family member 1 engagement inhibits T cell\u2013B cell interaction and diminishes interleukin\u20106 production and plasmablast differentiation in systemic lupus erythematosus. Arthritis & Rheumatology. 2018;71(1):99\u2013108. https:\/\/doi.org\/10.1002\/art.40682.","journal-title":"Arthritis & Rheumatology"},{"issue":"1","key":"1769_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood-2012-02-413831","volume":"121","author":"M Pihlgren","year":"2013","unstructured":"Pihlgren M, Silva AB, Madani R, Giriens V, Waeckerle-Men Y, Fettelschoss A, et al. TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell\u2013independent isotype switch in mice. Blood. 2013;121(1):85\u201394. https:\/\/doi.org\/10.1182\/blood-2012-02-413831.","journal-title":"Blood"},{"issue":"17","key":"1769_CR41","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","volume":"376","author":"M Steri","year":"2017","unstructured":"Steri M, Orr\u00f9 V, Idda ML, Pitzalis M, Pala M, Zara I, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017;376(17):1615\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1610528.","journal-title":"N Engl J Med"},{"issue":"6","key":"1769_CR42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/82717","volume":"1","author":"DP Harris","year":"2000","unstructured":"Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. 2000;1(6):475\u201382. https:\/\/doi.org\/10.1038\/82717.","journal-title":"Nat Immunol"},{"issue":"5","key":"1769_CR43","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.immuni.2008.03.017","volume":"28","author":"K Yanaba","year":"2008","unstructured":"Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5\u2009+\u2009phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28(5):639\u201350. https:\/\/doi.org\/10.1016\/j.immuni.2008.03.017.","journal-title":"Immunity"},{"key":"1769_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02535-6","author":"M Miao","year":"2021","unstructured":"Miao M, Xiao X, Tian J, Zhufeng Y, Feng R, Zhang R. Therapeutic potential of targeting Tfr\/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study. Arthritis Res Ther. 2021. https:\/\/doi.org\/10.1186\/s13075-021-02535-6.","journal-title":"Arthritis Res Ther"},{"key":"1769_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102647","author":"T Moser","year":"2020","unstructured":"Moser T, Akg\u00fcn K, Proschmann U, Sellner J, Ziemssen T. The role of TH17 cells in multiple sclerosis: therapeutic implications. Autoimmun Rev. 2020. https:\/\/doi.org\/10.1016\/j.autrev.2020.102647.","journal-title":"Autoimmun Rev"},{"key":"1769_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102976","author":"X Wei","year":"2023","unstructured":"Wei X, Niu X. T follicular helper cells in autoimmune diseases. J Autoimmun. 2023. https:\/\/doi.org\/10.1016\/j.jaut.2022.102976.","journal-title":"J Autoimmun"},{"issue":"7","key":"1769_CR47","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/annrheumdis-2021-221985","volume":"81","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Xu B, Wang S, Zhou M, Huang Y, Guo C, et al. Tfh cells with NLRP3 inflammasome activation are essential for high-affinity antibody generation, germinal centre formation and autoimmunity. Ann Rheum Dis. 2022;81(7):1006\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221985.","journal-title":"Ann Rheum Dis"},{"key":"1769_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47691-w","author":"J Tchen","year":"2024","unstructured":"Tchen J, Simon Q, Chapart L, Thaminy MK, Vibhushan S, Saveanu L. PD-L1- and IL-4-expressing basophils promote pathogenic accumulation of T follicular helper cells in lupus. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-47691-w.","journal-title":"Nat Commun"},{"issue":"7","key":"1769_CR49","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar M, Hafler DA. Regulatory T cells in autoimmune disease. Nat Immunol. 2018;19(7):665\u201373. https:\/\/doi.org\/10.1038\/s41590-018-0120-4.","journal-title":"Nat Immunol"},{"key":"1769_CR50","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122167","author":"C Jacquemin","year":"2018","unstructured":"Jacquemin C, Augusto J-F, Scherlinger M, Gensous N, Forcade E, Douchet I, et al. OX40L\/OX40 axis impairs follicular and natural Treg function in human SLE. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.122167.","journal-title":"JCI Insight"},{"key":"1769_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111606","author":"C Guo","year":"2022","unstructured":"Guo C, Liu Q, Zong D, Zhang W, Zuo Z, Yu Q, et al. Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4\u2009+\u2009T cell subset in systemic lupus erythematosus. Cell Rep. 2022. https:\/\/doi.org\/10.1016\/j.celrep.2022.111606.","journal-title":"Cell Rep"},{"issue":"5","key":"1769_CR52","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/art.40430","volume":"70","author":"C Liu","year":"2018","unstructured":"Liu C, Wang D, Lu S, Xu Q, Zhao L, Zhao J, et al. Increased circulating follicular Treg cells are associated with lower levels of autoantibodies in patients with rheumatoid arthritis in stable remission. Arthritis & Rheumatology. 2018;70(5):711\u201321. https:\/\/doi.org\/10.1002\/art.40430.","journal-title":"Arthritis & Rheumatology"},{"key":"1769_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102856","author":"J Liu","year":"2022","unstructured":"Liu J, Zhang X, Cao X. Dendritic cells in systemic lupus erythematosus: from pathogenesis to therapeutic applications. J Autoimmun. 2022. https:\/\/doi.org\/10.1016\/j.jaut.2022.102856.","journal-title":"J Autoimmun"},{"issue":"1","key":"1769_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3109\/03009742.2016.1158311","volume":"46","author":"MR Hillen","year":"2016","unstructured":"Hillen MR, Moret FM, van der Wurff-Jacobs KMG, Radstake T, Hack CE, Lafeber F, et al. Targeting CD1c-expressing classical dendritic cells to prevent thymus and activation-regulated chemokine (TARC)-mediated T-cell chemotaxis in rheumatoid arthritis. Scand J Rheumatol. 2016;46(1):11\u20136. https:\/\/doi.org\/10.3109\/03009742.2016.1158311.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"1769_CR55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1146\/annurev-immunol-090122-041105","volume":"42","author":"NM Adams","year":"2024","unstructured":"Adams NM, Das A, Yun TJ, Reizis B. Ontogeny and function of plasmacytoid dendritic cells. Annu Rev Immunol. 2024;42(1):347\u201373. https:\/\/doi.org\/10.1146\/annurev-immunol-090122-041105.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"1769_CR56","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.immuni.2020.04.015","volume":"52","author":"C Soni","year":"2020","unstructured":"Soni C, Perez OA, Voss WN, Pucella JN, Serpas L, Mehl J, et al. Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular Self-DNA. Immunity. 2020;52(6):1022\u2013e10381027. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.015.","journal-title":"Immunity"},{"issue":"7446","key":"1769_CR57","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature12034","volume":"496","author":"TA Wynn","year":"2013","unstructured":"Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496(7446):445\u201355. https:\/\/doi.org\/10.1038\/nature12034.","journal-title":"Nature"},{"key":"1769_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau0964","author":"S Chakarov","year":"2019","unstructured":"Chakarov S, Lim HY, Tan L, Lim SY, See P, Lum J, et al. Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science. 2019. https:\/\/doi.org\/10.1126\/science.aau0964.","journal-title":"Science"},{"key":"1769_CR59","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159751","author":"N Richoz","year":"2022","unstructured":"Richoz N, Tuong ZK, Loudon KW, Pati\u00f1o-Mart\u00ednez E, Ferdinand JR, Portet A, et al. Distinct pathogenic roles for resident and monocyte-derived macrophages in lupus nephritis. JCI Insight. 2022. https:\/\/doi.org\/10.1172\/jci.insight.159751.","journal-title":"JCI Insight"},{"key":"1769_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734008","author":"MM Ahamada","year":"2021","unstructured":"Ahamada MM, Jia Y, Wu X. Macrophage polarization and plasticity in systemic lupus erythematosus. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.734008.","journal-title":"Front Immunol"},{"issue":"5","key":"1769_CR61","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41577-022-00787-0","volume":"23","author":"G Wigerblad","year":"2022","unstructured":"Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2022;23(5):274\u201388. https:\/\/doi.org\/10.1038\/s41577-022-00787-0.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1769_CR62","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/ard-2022-223568","volume":"82","author":"LJ O'Neil","year":"2023","unstructured":"O\u2019Neil LJ, Oliveira CB, Wang X, Navarrete M, Barrera-Vargas A, Merayo-Chalico J, et al. Neutrophil extracellular trap-associated carbamylation and histones trigger osteoclast formation in rheumatoid arthritis. Ann Rheum Dis. 2023;82(5):630\u20138. https:\/\/doi.org\/10.1136\/ard-2022-223568.","journal-title":"Ann Rheum Dis"},{"key":"1769_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1050528","author":"D Giordano","year":"2023","unstructured":"Giordano D, Kuley R, Draves KE, Elkon KB, Giltiay NV, Clark EA. B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1050528.","journal-title":"Front Immunol"},{"issue":"2","key":"1769_CR64","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/annrheumdis-2018-213181","volume":"78","author":"E Frangou","year":"2019","unstructured":"Frangou E, Chrysanthopoulou A, Mitsios A, Kambas K, Arelaki S, Angelidou I, et al. REDD1\/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). Ann Rheum Dis. 2019;78(2):238\u201348. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213181.","journal-title":"Ann Rheum Dis"},{"key":"1769_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000387","author":"KA Fortner","year":"2020","unstructured":"Fortner KA, Blanco LP, Buskiewicz I, Huang N, Gibson PC, Cook DL, et al. Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lprmice. Lupus Sci Med. 2020. https:\/\/doi.org\/10.1136\/lupus-2020-000387.","journal-title":"Lupus Sci Med"},{"issue":"2","key":"1769_CR66","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.autrev.2017.11.018","volume":"17","author":"E Gianchecchi","year":"2018","unstructured":"Gianchecchi E, Delfino DV, Fierabracci A. NK cells in autoimmune diseases: linking innate and adaptive immune responses. Autoimmun Rev. 2018;17(2):142\u201354. https:\/\/doi.org\/10.1016\/j.autrev.2017.11.018.","journal-title":"Autoimmun Rev"},{"key":"1769_CR67","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/o6bjl8","author":"H Li","year":"2022","unstructured":"Li H, Geng L, Cao Z, Jin Z, Yan Q, Long X, et al. CD56brightCD16- to CD57\u2009+\u2009CD56dimCD16\u2009+\u2009NK cell ratio discriminates disease activity and renal involvement in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2022. https:\/\/doi.org\/10.55563\/clinexprheumatol\/o6bjl8.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"1769_CR68","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20(7):902\u201314. https:\/\/doi.org\/10.1038\/s41590-019-0398-x.","journal-title":"Nat Immunol"},{"key":"1769_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35209-1","author":"M Zheng","year":"2022","unstructured":"Zheng M, Hu Z, Mei X, Ouyang L, Song Y, Zhou W, et al. Single-cell sequencing shows cellular heterogeneity of cutaneous lesions in lupus erythematosus. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/s41467-022-35209-1.","journal-title":"Nat Commun"},{"key":"1769_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645478","author":"M Humbel","year":"2021","unstructured":"Humbel M, Bellanger F, Fluder N, Horisberger A, Suffiotti M, Fenwick C, et al. Restoration of NK cell cytotoxic function with elotuzumab and daratumumab promotes elimination of circulating plasma cells in patients with SLE. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.645478.","journal-title":"Front Immunol"},{"issue":"2","key":"1769_CR71","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/cei\/uxab035","volume":"207","author":"A Scheffschick","year":"2022","unstructured":"Scheffschick A, Fuchs S, Malmstr\u00f6m V, Gunnarsson I, Brauner H. Kidney infiltrating NK cells and NK-like T-cells in lupus nephritis: presence, localization, and the effect of immunosuppressive treatment. Clin Exp Immunol. 2022;207(2):199\u2013204. https:\/\/doi.org\/10.1093\/cei\/uxab035.","journal-title":"Clin Exp Immunol"},{"key":"1769_CR72","doi-asserted-by":"publisher","DOI":"10.18502\/ijaai.v23i3.15639","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang M, Chen S, Li Z, Meng M. Invariant natural killer cells regulate conventional dendritic cell maturation to re-establish immune tolerance to rheumatoid arthritis in DBA\/1 mice. Iran J Allergy Asthma Immunol. 2024. https:\/\/doi.org\/10.18502\/ijaai.v23i3.15639.","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"2","key":"1769_CR73","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/eji.201444760","volume":"45","author":"L Shen","year":"2014","unstructured":"Shen L, Zhang H, Caimol M, Benike CJ, Chakravarty EF, Strober S, et al. Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production. Eur J Immunol. 2014;45(2):612\u201323. https:\/\/doi.org\/10.1002\/eji.201444760.","journal-title":"Eur J Immunol"},{"key":"1769_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo1930","author":"I Alves","year":"2023","unstructured":"Alves I, Santos-Pereira B, de la Cruz N, Campar A, Pinto V, Rodrigues PM, et al. Host-derived mannose glycans trigger a pathogenic \u03b3\u03b4 T cell\/IL-17a axis in autoimmunity. Sci Transl Med. 2023. https:\/\/doi.org\/10.1126\/scitranslmed.abo1930.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1769_CR75","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/imm.12809","volume":"153","author":"J Ngoenkam","year":"2017","unstructured":"Ngoenkam J, Schamel WW, Pongcharoen S. Selected signalling proteins recruited to the T-cell receptor\u2013CD3 complex. Immunology. 2017;153(1):42\u201350. https:\/\/doi.org\/10.1111\/imm.12809.","journal-title":"Immunology"},{"issue":"2","key":"1769_CR76","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1053\/j.gastro.2021.10.037","volume":"162","author":"S Ben-Horin","year":"2022","unstructured":"Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, et al. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology. 2022;162(2):482\u201394. https:\/\/doi.org\/10.1053\/j.gastro.2021.10.037.","journal-title":"Gastroenterology"},{"key":"1769_CR77","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","volume":"141","author":"JL Karnell","year":"2019","unstructured":"Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv Drug Deliv Rev. 2019;141:92\u2013103. https:\/\/doi.org\/10.1016\/j.addr.2018.12.005.","journal-title":"Adv Drug Deliv Rev"},{"key":"1769_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03547-2","author":"A Merino-Vico","year":"2025","unstructured":"Merino-Vico A, Kocyigit M, Frazzei G, Landman L, Boon L, van Leeuwen EM, et al. Modulating IL-21-driven B cell responses in idiopathic inflammatory myopathies via inhibition of the JAK\/STAT pathway. Arthritis Res Ther. 2025. https:\/\/doi.org\/10.1186\/s13075-025-03547-2.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"1769_CR79","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.immuni.2024.07.016","volume":"57","author":"ME Raeber","year":"2024","unstructured":"Raeber ME, Caspar DP, Zurbuchen Y, Guo N, Schmid J, Michler J, et al. Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity. 2024;57(9):2232\u2013e22502210. https:\/\/doi.org\/10.1016\/j.immuni.2024.07.016.","journal-title":"Immunity"},{"issue":"12","key":"1769_CR80","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J, et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis. 2022;81(12):1685\u201394. https:\/\/doi.org\/10.1136\/ard-2022-222501.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1769_CR81","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.7326\/m21-2078","volume":"174","author":"M Shipa","year":"2021","unstructured":"Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus. Ann Intern Med. 2021;174(12):1647\u201357. https:\/\/doi.org\/10.7326\/m21-2078.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1769_CR82","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","volume":"392","author":"JH Stone","year":"2025","unstructured":"Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, et al. Inebilizumab for treatment of IgG4-related disease. N Engl J Med. 2025;392(12):1168\u201377. https:\/\/doi.org\/10.1056\/NEJMoa2409712.","journal-title":"N Engl J Med"},{"issue":"1","key":"1769_CR83","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2009","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to\u2010severely active systemic lupus erythematosus: the randomized, double\u2010blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2009;62(1):222\u201333. https:\/\/doi.org\/10.1002\/art.27233.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1769_CR84","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/ajt.12220","volume":"13","author":"EG Kamburova","year":"2013","unstructured":"Kamburova EG, Koenen HJPM, Borgman KJE, ten Berge IJ, Joosten I, Hilbrands LB. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant. 2013;13(6):1503\u201311. https:\/\/doi.org\/10.1111\/ajt.12220.","journal-title":"Am J Transplant"},{"key":"1769_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103410","author":"JJ Knox","year":"2025","unstructured":"Knox JJ, Scholz JL, Futeran H, Cataliotti S, Cancro MP. T-bet\u2009+\u2009CD11c\u2009+\u2009age-associated B cells resist BLyS- and CD20-targeted ablation in murine lupus models. J Autoimmun. 2025. https:\/\/doi.org\/10.1016\/j.jaut.2025.103410.","journal-title":"J Autoimmun"},{"issue":"11","key":"1769_CR86","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/ard-2024-225727","volume":"83","author":"G Schett","year":"2024","unstructured":"Schett G, Nagy G, Kronke G, Mielenz D. B-cell depletion in autoimmune diseases. Ann Rheum Dis. 2024;83(11):1409\u201320. https:\/\/doi.org\/10.1136\/ard-2024-225727.","journal-title":"Ann Rheum Dis"},{"key":"1769_CR87","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418761697","author":"TG Forsthuber","year":"2018","unstructured":"Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, St\u00fcve O. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. 2018. https:\/\/doi.org\/10.1177\/1756286418761697.","journal-title":"Ther Adv Neurol Disord"},{"key":"1769_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.09.020","author":"C Qin","year":"2025","unstructured":"Qin C, Dong M-H, Zhou L-Q, Chu Y-H, Pang X-W, He J-Y, et al. Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. Cell. 2025. https:\/\/doi.org\/10.1016\/j.cell.2025.09.020.","journal-title":"Cell"},{"issue":"6","key":"1769_CR89","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567\u20139. https:\/\/doi.org\/10.1056\/NEJMc2107725.","journal-title":"N Engl J Med"},{"issue":"10","key":"1769_CR90","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332. https:\/\/doi.org\/10.1038\/s41591-022-02017-5.","journal-title":"Nat Med"},{"issue":"10379","key":"1769_CR91","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/s0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, Boeltz S, Knitza J, Aigner M, V\u00f6lkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379):815\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(23)00023-5.","journal-title":"Lancet"},{"key":"1769_CR92","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8753","author":"A-C Pecher","year":"2023","unstructured":"Pecher A-C, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023. https:\/\/doi.org\/10.1001\/jama.2023.8753.","journal-title":"JAMA"},{"issue":"7","key":"1769_CR93","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/s1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M, Miljkovi\u0107 MD, Chahin N, Sahagian G, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 2023;22(7):578\u201390. https:\/\/doi.org\/10.1016\/s1474-4422(23)00194-1.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1769_CR94","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"issue":"12","key":"1769_CR95","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/s1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, B\u00f6ttcher M, Desel C, Borie D, et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 2023;22(12):1104\u20135. https:\/\/doi.org\/10.1016\/s1474-4422(23)00375-7.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1769_CR96","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt W, Freitag M, Claus M, Kolb P, Falcone V, R\u00f6hrich M, et al. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70\u2009+\u2009systemic sclerosis. Ann Rheum Dis. 2024;83(4):543\u20136. https:\/\/doi.org\/10.1136\/ard-2023-225174.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1769_CR97","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024;5(6):550\u2013e558552. https:\/\/doi.org\/10.1016\/j.medj.2024.03.002.","journal-title":"Med"},{"key":"1769_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01278-3","author":"C Qin","year":"2023","unstructured":"Qin C, Tian D-S, Zhou L-Q, Shang K, Huang L, Dong M-H, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023. https:\/\/doi.org\/10.1038\/s41392-022-01278-3.","journal-title":"Signal Transduct Target Ther"},{"key":"1769_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00890-6","author":"Y Tian","year":"2020","unstructured":"Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020. https:\/\/doi.org\/10.1186\/s13045-020-00890-6.","journal-title":"J Hematol Oncol"},{"key":"1769_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00417-w","author":"M Mazinani","year":"2022","unstructured":"Mazinani M, Rahbarizadeh F. CAR-T cell potency: from structural elements to vector backbone components. Biomark Res. 2022. https:\/\/doi.org\/10.1186\/s40364-022-00417-w.","journal-title":"Biomark Res"},{"key":"1769_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, et al. CAR-T design: elements and their synergistic function. EBioMedicine. 2020. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102931.","journal-title":"EBioMedicine"},{"key":"1769_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"key":"1769_CR103","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-04089-x","author":"Y Duan","year":"2021","unstructured":"Duan Y, Chen R, Huang Y, Meng X, Chen J, Liao C, et al. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell Mol Life Sci. 2021. https:\/\/doi.org\/10.1007\/s00018-021-04089-x.","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"1769_CR104","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/s41375-021-01269-3","volume":"35","author":"L Han","year":"2021","unstructured":"Han L, Zhang J-S, Zhou J, Zhou K-S, Xu B-L, Li L-L, et al. Single VHH-directed BCMA CAR-T cells cause remission of relapsed\/refractory multiple myeloma. Leukemia. 2021;35(10):3002\u20136. https:\/\/doi.org\/10.1038\/s41375-021-01269-3.","journal-title":"Leukemia"},{"issue":"4","key":"1769_CR105","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/2326-6066.cir-19-0734","volume":"8","author":"YJ Xie","year":"2020","unstructured":"Xie YJ, Dougan M, Ingram JR, Pishesha N, Fang T, Momin N, et al. Improved antitumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments. Cancer Immunol Res. 2020;8(4):518\u201329. https:\/\/doi.org\/10.1158\/2326-6066.cir-19-0734.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"1769_CR106","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1016\/j.apsb.2024.08.023","volume":"14","author":"X Xi","year":"2024","unstructured":"Xi X, Wang Y, An G, Feng S, Zhu Q, Wu Z, et al. A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy. Acta Pharm Sin B. 2024;14(11):4806\u201318. https:\/\/doi.org\/10.1016\/j.apsb.2024.08.023.","journal-title":"Acta Pharm Sin B"},{"issue":"Supplement_1","key":"1769_CR107","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2019-126689","volume":"134","author":"R Popat","year":"2019","unstructured":"Popat R, Zweegman S, Cavet J, Yong K, Lee L, Faulkner J, et al. Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2019;134(Supplement_1):3112\u20133112. https:\/\/doi.org\/10.1182\/blood-2019-126689.","journal-title":"Blood"},{"key":"1769_CR108","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw9414","author":"H Qin","year":"2019","unstructured":"Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aaw9414.","journal-title":"Sci Transl Med"},{"key":"1769_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27853-w","author":"DP Wong","year":"2022","unstructured":"Wong DP, Roy NK, Zhang K, Anukanth A, Asthana A, Shirkey-Son NJ, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/s41467-021-27853-w.","journal-title":"Nat Commun"},{"issue":"12","key":"1769_CR110","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/s41551-024-01258-8","volume":"8","author":"Z Xia","year":"2024","unstructured":"Xia Z, Jin Q, Long Z, He Y, Liu F, Sun C, et al. Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders. Nat Biomed Eng. 2024;8(12):1634\u201350. https:\/\/doi.org\/10.1038\/s41551-024-01258-8.","journal-title":"Nat Biomed Eng"},{"key":"1769_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0099-4","author":"JA Hammill","year":"2015","unstructured":"Hammill JA, VanSeggelen H, Helsen CW, Denisova GF, Evelegh C, Tantalo DGM, et al. Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. J Immunother Cancer. 2015. https:\/\/doi.org\/10.1186\/s40425-015-0099-4.","journal-title":"J Immunother Cancer"},{"key":"1769_CR112","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2341443","author":"M Mullin","year":"2024","unstructured":"Mullin M, McClory J, Haynes W, Grace J, Robertson N, van Heeke G. Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions. mAbs. 2024. https:\/\/doi.org\/10.1080\/19420862.2024.2341443.","journal-title":"mAbs"},{"key":"1769_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02512-6","author":"Q Lu","year":"2024","unstructured":"Lu Q, Li H, Wu Z, Zhu Z, Zhang Z, Yang D, et al. BCMA\/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma. J Nanobiotechnology. 2024. https:\/\/doi.org\/10.1186\/s12951-024-02512-6.","journal-title":"J Nanobiotechnology"},{"key":"1769_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47801-8","author":"M Shi","year":"2024","unstructured":"Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-47801-8.","journal-title":"Nat Commun"},{"issue":"9","key":"1769_CR115","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.mct-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina A, Maher J. Strategies to address chimeric antigen receptor tonic signaling. Mol Cancer Ther. 2018;17(9):1795\u2013815. https:\/\/doi.org\/10.1158\/1535-7163.mct-17-1097.","journal-title":"Mol Cancer Ther"},{"key":"1769_CR116","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010208","author":"M Barden","year":"2024","unstructured":"Barden M, Elsenbroich PR, Haas V, Ertelt M, Pervan P, Velas L. Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-010208.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1769_CR117","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/2326-6066.cir-22-0423","volume":"11","author":"D Rasoulouniriana","year":"2023","unstructured":"Rasoulouniriana D, Santana-Magal N, Gutwillig A, Farhat-Younis L, Tal L, Amar S, et al. T cells expressing a modified Fc\u03b3RI exert antibody-dependent cytotoxicity and overcome the limitations of CAR T-cell therapy against solid tumors. Cancer Immunol Res. 2023;11(6):792\u2013809. https:\/\/doi.org\/10.1158\/2326-6066.cir-22-0423.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"1769_CR118","doi-asserted-by":"publisher","first-page":"10189","DOI":"10.1007\/s00432-023-04865-1","volume":"149","author":"L Sun","year":"2023","unstructured":"Sun L, Jiang G, Ng YY, Xiao L, Du Z, Wang S, et al. T cells with split cars specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo. J Cancer Res Clin Oncol. 2023;149(12):10189\u2013201. https:\/\/doi.org\/10.1007\/s00432-023-04865-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"1769_CR119","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X Hua","year":"2020","unstructured":"Hua X, June CH, Siegel DL, O\u2019Dwyer KP, Katona BW, Wu Y, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713\u201323. https:\/\/doi.org\/10.1182\/blood.2019002779.","journal-title":"Blood"},{"key":"1769_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01288-2","author":"P Lai","year":"2022","unstructured":"Lai P, Chen X, Wang Y, Wang J, Zhang Y, Geng S. C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction. J Hematol Oncol. 2022. https:\/\/doi.org\/10.1186\/s13045-022-01288-2.","journal-title":"J Hematol Oncol"},{"key":"1769_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01128-9","author":"N Pang","year":"2021","unstructured":"Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021. https:\/\/doi.org\/10.1186\/s13045-021-01128-9.","journal-title":"J Hematol Oncol"},{"key":"1769_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091303","author":"MM Honikel","year":"2022","unstructured":"Honikel MM, Olejniczak SH. Co-stimulatory receptor signaling in CAR-T cells. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12091303.","journal-title":"Biomolecules"},{"issue":"1","key":"1769_CR123","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 2017;21(1):17\u201326. https:\/\/doi.org\/10.1016\/j.celrep.2017.09.015.","journal-title":"Cell Rep"},{"issue":"1","key":"1769_CR124","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, Rivi\u00e8re I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6 \/CD28 receptor. Nat Biotechnol. 2002;20(1):70\u20135. https:\/\/doi.org\/10.1038\/nbt0102-70.","journal-title":"Nat Biotechnol"},{"key":"1769_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00450-x","author":"M Liu","year":"2023","unstructured":"Liu M, Zhang L, Zhong M, Long Y, Yang W, Liu T. CRISPR\/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro. Exp Hematol Oncol. 2023. https:\/\/doi.org\/10.1186\/s40164-023-00450-x.","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"1769_CR126","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41590-023-01658-z","volume":"24","author":"RMH Velasco C\u00e1rdenas","year":"2023","unstructured":"Velasco C\u00e1rdenas RMH, Brandl SM, Mel\u00e9ndez AV, Schlaak AE, Buschky A, Peters T, et al. Harnessing CD3 diversity to optimize CAR T cells. Nat Immunol. 2023;24(12):2135\u201349. https:\/\/doi.org\/10.1038\/s41590-023-01658-z.","journal-title":"Nat Immunol"},{"issue":"3","key":"1769_CR127","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","volume":"37","author":"DT Harris","year":"2016","unstructured":"Harris DT, Kranz DM. Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci. 2016;37(3):220\u201330. https:\/\/doi.org\/10.1016\/j.tips.2015.11.004.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1769_CR128","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2018","unstructured":"Feucht J, Sun J, Eyquem J, Ho Y-J, Zhao Z, Leibold J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med. 2018;25(1):82\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0290-5.","journal-title":"Nat Med"},{"key":"1769_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0460-5","author":"MM Boyiadzis","year":"2018","unstructured":"Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018. https:\/\/doi.org\/10.1186\/s40425-018-0460-5.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"1769_CR130","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.ccell.2022.08.001","volume":"40","author":"N Zheng","year":"2022","unstructured":"Zheng N, Fang J, Xue G, Wang Z, Li X, Zhou M, et al. Induction of tumor cell autosis by Myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance. Cancer Cell. 2022;40(9):973\u2013e985977. https:\/\/doi.org\/10.1016\/j.ccell.2022.08.001.","journal-title":"Cancer Cell"},{"key":"1769_CR131","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl3995","author":"Q Xiao","year":"2022","unstructured":"Xiao Q, Zhang X, Tu L, Cao J, Hinrichs CS, Su X. Size-dependent activation of CAR-T cells. Sci Immunol. 2022. https:\/\/doi.org\/10.1126\/sciimmunol.abl3995.","journal-title":"Sci Immunol"},{"issue":"2","key":"1769_CR132","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the Immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720\u20134. https:\/\/doi.org\/10.1073\/pnas.90.2.720.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"1769_CR133","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/1535370215584936","volume":"240","author":"AE Firor","year":"2015","unstructured":"Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Experimental Biology Med. 2015;240(8):1087\u201398. https:\/\/doi.org\/10.1177\/1535370215584936.","journal-title":"Experimental Biology Med"},{"issue":"6","key":"1769_CR134","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/00002371-200011000-00004","volume":"23","author":"EJ Beecham","year":"2000","unstructured":"Beecham EJ, Ma Q, Ripley R, Junghans RP. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death. J Immunother. 2000;23(6):631\u201342. https:\/\/doi.org\/10.1097\/00002371-200011000-00004.","journal-title":"J Immunother"},{"issue":"4","key":"1769_CR135","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen Sjoukje JC, Perna F, Kloss Christopher C, Gunset G, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415\u201328. https:\/\/doi.org\/10.1016\/j.ccell.2015.09.004.","journal-title":"Cancer Cell"},{"issue":"4","key":"1769_CR136","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","volume":"26","author":"Z Cheng","year":"2018","unstructured":"Cheng Z, Wei R, Ma Q, Shi L, He F, Shi Z, et al. In vivo expansion and antitumor activity of coinfused CD28- and 4-1BB-engineered CAR-T cells in patients with B cell leukemia. Mol Ther. 2018;26(4):976\u201385. https:\/\/doi.org\/10.1016\/j.ymthe.2018.01.022.","journal-title":"Mol Ther"},{"issue":"8","key":"1769_CR137","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453\u201364. https:\/\/doi.org\/10.1038\/mt.2009.83.","journal-title":"Mol Ther"},{"key":"1769_CR138","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121322","author":"G Li","year":"2018","unstructured":"Li G, Boucher JC, Kotani H, Park K, Zhang Y, Shrestha B. 4-1BB enhancement of CAR T function requires NF-\u03baB and TRAFs. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.121322.","journal-title":"JCI Insight"},{"key":"1769_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.00128.","journal-title":"Front Immunol"},{"key":"1769_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1034707","author":"J Tomasik","year":"2022","unstructured":"Tomasik J, Jasi\u0144ski M, Basak GW. Next generations of CAR-T cells - new therapeutic opportunities in hematology? Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.1034707.","journal-title":"Front Immunol"},{"issue":"11","key":"1769_CR141","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","volume":"38","author":"P Derigs","year":"2024","unstructured":"Derigs P, Schubert M-L, Dreger P, Schmitt A, Yousefian S, Haas S, et al. Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: a phase 1\/2 study. Leukemia. 2024;38(11):2419\u201328. https:\/\/doi.org\/10.1038\/s41375-024-02392-7.","journal-title":"Leukemia"},{"issue":"8","key":"1769_CR142","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145\u201354. https:\/\/doi.org\/10.1517\/14712598.2015.1046430.","journal-title":"Expert Opin Biol Ther"},{"key":"1769_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609421","author":"D Duan","year":"2021","unstructured":"Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, et al. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.609421.","journal-title":"Front Immunol"},{"key":"1769_CR144","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000733","author":"I Etxeberria","year":"2019","unstructured":"Etxeberria I, Glez-Vaz J, Teijeira \u00c1, Melero I. New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis. ESMO Open. 2019. https:\/\/doi.org\/10.1136\/esmoopen-2020-000733.","journal-title":"ESMO Open"},{"issue":"3","key":"1769_CR145","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/eji.201445388","volume":"46","author":"AR Sanchez-Paulete","year":"2016","unstructured":"Sanchez-Paulete AR, Labiano S, Rodriguez\u2010Ruiz ME, Azpilikueta A, Etxeberria I, Bola\u00f1os E, et al. Deciphering CD137 (4\u20101BB) signaling in T\u2010cell costimulation for translation into successful cancer immunotherapy. Eur J Immunol. 2016;46(3):513\u201322. https:\/\/doi.org\/10.1002\/eji.201445388.","journal-title":"Eur J Immunol"},{"key":"1769_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1248867","author":"N Schaft","year":"2023","unstructured":"Schaft N, D\u00f6rrie J, Schuler G, Schuler-Thurner B, Sallam H, Klein S, et al. The future of affordable cancer immunotherapy. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1248867.","journal-title":"Front Immunol"},{"key":"1769_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112667","author":"LRC Barros","year":"2022","unstructured":"Barros LRC, Couto SCF, da Silva Santurio D, Paix\u00e3o EA, Cardoso F, da Silva VJ, et al. Systematic review of available CAR-T cell trials around the world. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14112667.","journal-title":"Cancers"},{"key":"1769_CR148","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355. https:\/\/doi.org\/10.1016\/j.blre.2018.11.002.","journal-title":"Blood Rev"},{"key":"1769_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01648-0","author":"Y Liu","year":"2024","unstructured":"Liu Y, An L, Wang X, Dai Y, Zhang C, Wen Q, et al. Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system. J Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s13045-024-01648-0.","journal-title":"J Hematol Oncol"},{"key":"1769_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01701-6","author":"H Qin","year":"2025","unstructured":"Qin H, Zhou Z, Shi R, Mai Y, Xu Y, Peng F, et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J Hematol Oncol. 2025. https:\/\/doi.org\/10.1186\/s13045-025-01701-6.","journal-title":"J Hematol Oncol"},{"key":"1769_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01530-z","author":"J Xu","year":"2024","unstructured":"Xu J, Wang B-Y, Yu S-H, Chen S-J, Yang S-S, Liu R, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s13045-024-01530-z.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1769_CR152","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/ajh.25108","volume":"93","author":"J Cao","year":"2018","unstructured":"Cao J, Wang G, Cheng H, Wei C, Qi K, Sang W, et al. Potent anti-leukemia activities of humanized CD19\u2010targeted Chimeric antigen receptor T (CAR\u2010T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol. 2018;93(7):851\u20138. https:\/\/doi.org\/10.1002\/ajh.25108.","journal-title":"Am J Hematol"},{"issue":"5","key":"1769_CR153","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/jco.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, et al. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2020;38(5):415\u201322. https:\/\/doi.org\/10.1200\/jco.19.01892.","journal-title":"J Clin Oncol"},{"key":"1769_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1490491","author":"X Ye","year":"2025","unstructured":"Ye X, Ge M, Tan M, Wu Y, Zhang H, Fu Z. CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security? Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1490491.","journal-title":"Front Immunol"},{"issue":"10","key":"1769_CR155","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/s2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6(10):e521\u20139. https:\/\/doi.org\/10.1016\/s2352-3026(19)30115-2.","journal-title":"Lancet Haematol"},{"issue":"20","key":"1769_CR156","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/jco.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, et al. Long-term follow-up of combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol. 2022;40(20):2246\u201356. https:\/\/doi.org\/10.1200\/jco.21.01676.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1769_CR157","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024;83(10):1304\u201314. https:\/\/doi.org\/10.1136\/ard-2024-225785.","journal-title":"Ann Rheum Dis"},{"key":"1769_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/ph18020156","author":"A Hern\u00e1ndez-L\u00f3pez","year":"2025","unstructured":"Hern\u00e1ndez-L\u00f3pez A, Olaya-Vargas A, Bustamante-Ogando JC, Meneses-Acosta A. Expanding the horizons of CAR-T cell therapy: a review of therapeutic targets across diverse diseases. Pharmaceuticals. 2025. https:\/\/doi.org\/10.3390\/ph18020156.","journal-title":"Pharmaceuticals"},{"issue":"9","key":"1769_CR159","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia Gravis with chimeric autoantibody receptor T cells. Nat Biotechnol. 2023;41(9):1229\u201338. https:\/\/doi.org\/10.1038\/s41587-022-01637-z.","journal-title":"Nat Biotechnol"},{"issue":"6295","key":"1769_CR160","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179\u201384. https:\/\/doi.org\/10.1126\/science.aaf6756.","journal-title":"Science"},{"key":"1769_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-025-01086-8","author":"T Enbar","year":"2025","unstructured":"Enbar T, Tang L. Mimicking the TCR immune synapse for improved CAR-T cell function. Cell Res. 2025. https:\/\/doi.org\/10.1038\/s41422-025-01086-8.","journal-title":"Cell Res"},{"key":"1769_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101023","author":"JA Rohrs","year":"2020","unstructured":"Rohrs JA, Siegler EL, Wang P, Finley SD. ERK activation in CAR T cells is amplified by CD28-mediated increase in CD3\u03b6 phosphorylation. iScience. 2020. https:\/\/doi.org\/10.1016\/j.isci.2020.101023.","journal-title":"iScience"},{"key":"1769_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202002628","author":"R Li","year":"2020","unstructured":"Li R, Ma C, Cai H, Chen W. The CAR T-cell mechanoimmunology at a glance. Adv Sci. 2020. https:\/\/doi.org\/10.1002\/advs.202002628.","journal-title":"Adv Sci"},{"key":"1769_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","author":"M-R Benmebarek","year":"2019","unstructured":"Benmebarek M-R, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20061283.","journal-title":"Int J Mol Sci"},{"key":"1769_CR165","doi-asserted-by":"publisher","unstructured":"Montalvo MJ, Bandey IN, Rezvan A, Wu K-L, Saeedi A, Kulkarni R, et al. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas Inhibition. Cell Death Dis. 2024;15(2). https:\/\/doi.org\/10.1038\/s41419-024-06461-8.","DOI":"10.1038\/s41419-024-06461-8"},{"issue":"3","key":"1769_CR166","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/2159-8290.cd-20-0756","volume":"11","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 2021;11(3):599\u2013613. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-0756.","journal-title":"Cancer Discov"},{"key":"1769_CR167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.947648","author":"CRF Silveira","year":"2022","unstructured":"Silveira CRF, Corveloni AC, Caruso SR, Mac\u00eado NA, Brussolo NM, Haddad F. Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.947648.","journal-title":"Front Immunol"},{"key":"1769_CR168","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1090959","author":"S Thomas","year":"2023","unstructured":"Thomas S, Abken H. CAR T cell therapy becomes CHIC: \u201ccytokine help intensified CAR\u201d T cells. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2022.1090959.","journal-title":"Front Immunol"},{"key":"1769_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20893-2","author":"A Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, O\u2019Connor RS. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 2021. https:\/\/doi.org\/10.1038\/s41467-021-20893-2.","journal-title":"Nat Commun"},{"key":"1769_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04061-2","author":"Y Huo","year":"2023","unstructured":"Huo Y, Zhang H, Sa L, Zheng W, He Y, Lyu H. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J Transl Med. 2023. https:\/\/doi.org\/10.1186\/s12967-023-04061-2.","journal-title":"J Transl Med"},{"issue":"9","key":"1769_CR171","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. CAR-T cells secreting bites circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37(9):1049\u201358. https:\/\/doi.org\/10.1038\/s41587-019-0192-1.","journal-title":"Nat Biotechnol"},{"key":"1769_CR172","doi-asserted-by":"publisher","unstructured":"Kara E, Jackson TL, Jones C, Sison R, McGee Ii RL. Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects. Npj Syst Biology Appl. 2024;10(1). https:\/\/doi.org\/10.1038\/s41540-024-00435-4.","DOI":"10.1038\/s41540-024-00435-4"},{"key":"1769_CR173","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02079-8","author":"X Xia","year":"2024","unstructured":"Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024. https:\/\/doi.org\/10.1186\/s12943-024-02079-8.","journal-title":"Mol Cancer"},{"issue":"8","key":"1769_CR174","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1158\/2326-6066.cir-21-0536","volume":"10","author":"RA Brog","year":"2022","unstructured":"Brog RA, Ferry SL, Schiebout CT, Messier CM, Cook WJ, Abdullah L, et al. Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors. Cancer Immunol Res. 2022;10(8):962\u201377. https:\/\/doi.org\/10.1158\/2326-6066.cir-21-0536.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1769_CR175","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2016;27(1):109\u201318. https:\/\/doi.org\/10.1038\/cr.2016.151.","journal-title":"Cell Res"},{"key":"1769_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0760-3","author":"Y Lin","year":"2019","unstructured":"Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019. https:\/\/doi.org\/10.1186\/s13045-019-0760-3.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"1769_CR177","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","volume":"3","author":"NN Shah","year":"2019","unstructured":"Shah NN, Qin H, Yates B, Su L, Shalabi H, Raffeld M, et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 2019;3(15):2317\u201322. https:\/\/doi.org\/10.1182\/bloodadvances.2019000219.","journal-title":"Blood Adv"},{"key":"1769_CR178","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065688","author":"V Wittibschlager","year":"2023","unstructured":"Wittibschlager V, Bacher U, Seipel K, Porret N, Wiedemann G, Haslebacher C, et al. CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065688.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1769_CR179","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2215\/cjn.10570918","volume":"14","author":"X Huang","year":"2019","unstructured":"Huang X, Chen W, Ren G, Zhao L, Guo J, Gong D, et al. Autologous hematopoietic stem cell transplantation for refractory lupus nephritis. Clin J Am Soc Nephrol. 2019;14(5):719\u201327. https:\/\/doi.org\/10.2215\/cjn.10570918.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"1769_CR180","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, M\u00fcller F, Taubmann J, Mackensen A, Wang W, Furie RA, et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;20(9):531\u201344. https:\/\/doi.org\/10.1038\/s41584-024-01139-z.","journal-title":"Nat Rev Rheumatol"},{"key":"1769_CR181","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200027","author":"V von Niederh\u00e4usern","year":"2022","unstructured":"von Niederh\u00e4usern V, Ruder J, Ghraichy M, Jelcic I, M\u00fcller AM, Schanz U, et al. B-cell reconstitution after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022. https:\/\/doi.org\/10.1212\/nxi.0000000000200027.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1769_CR182","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1889-8","author":"M Gernert","year":"2019","unstructured":"Gernert M, Tony H-P, Schwaneck EC, Gadeholt O, Schmalzing M. Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern. Arthritis Res Ther. 2019. https:\/\/doi.org\/10.1186\/s13075-019-1889-8.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1769_CR183","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","volume":"2","author":"LCM Arruda","year":"2018","unstructured":"Arruda LCM, Malmegrim KCR, Lima-J\u00fanior JR, Clave E, Dias JBE, Moraes DA, et al. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. Blood Adv. 2018;2(2):126\u201341. https:\/\/doi.org\/10.1182\/bloodadvances.2017011072.","journal-title":"Blood Adv"},{"issue":"3","key":"1769_CR184","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1136\/ard-2021-221925","volume":"82","author":"JZ Adamska","year":"2023","unstructured":"Adamska JZ, Zia A, Bloom MS, Crofford LJ, Furst DE, Goldmuntz E, et al. Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more na\u00efve state in patients with systemic sclerosis. Ann Rheum Dis. 2023;82(3):357\u201364. https:\/\/doi.org\/10.1136\/ard-2021-221925.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1769_CR185","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1093\/rheumatology\/keab877","volume":"61","author":"S Goklemez","year":"2022","unstructured":"Goklemez S, Hasni S, Hakim FT, Muraro PA, Pirsl F, Rose J, et al. Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus. Rheumatology. 2022;61(8):3317\u201328. https:\/\/doi.org\/10.1093\/rheumatology\/keab877.","journal-title":"Rheumatology"},{"issue":"6753","key":"1769_CR186","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u20137. https:\/\/doi.org\/10.1126\/science.ads8473.","journal-title":"Science"},{"issue":"1","key":"1769_CR187","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","volume":"113","author":"T Alexander","year":"2009","unstructured":"Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113(1):214\u201323. https:\/\/doi.org\/10.1182\/blood-2008-07-168286.","journal-title":"Blood"},{"issue":"11","key":"1769_CR188","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24(11):830\u201345. https:\/\/doi.org\/10.1038\/s41577-024-01035-3.","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"1769_CR189","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/jco.2013.50.0892","volume":"32","author":"BM Weiss","year":"2014","unstructured":"Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol. 2014;32(25):2699\u2013704. https:\/\/doi.org\/10.1200\/jco.2013.50.0892.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1769_CR190","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.cd-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398. https:\/\/doi.org\/10.1158\/2159-8290.cd-12-0548.","journal-title":"Cancer Discov"},{"issue":"4","key":"1769_CR191","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1378\/chest.117.4.1162","volume":"117","author":"SM Opal","year":"2000","unstructured":"Opal SM, DePalo VA, Anti-Inflammatory, Cytokines. Chest. 2000;117(4):1162\u201372. https:\/\/doi.org\/10.1378\/chest.117.4.1162.","journal-title":"Chest"},{"key":"1769_CR192","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1465191","author":"A Cheever","year":"2024","unstructured":"Cheever A, Kang CC, O\u2019Neill KL, Weber KS. Application of novel CAR technologies to improve treatment of autoimmune disease. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1465191.","journal-title":"Front Immunol"},{"key":"1769_CR193","doi-asserted-by":"publisher","DOI":"10.1172\/jci168601","author":"JA Spanier","year":"2023","unstructured":"Spanier JA, Fung V, Wardell CM, Alkhatib MH, Chen Y, Swanson LA, et al. Insulin B peptide-MHC class II-specific chimeric antigen receptor-Tregs prevent autoimmune diabetes in mice. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/jci168601.","journal-title":"J Clin Invest"},{"issue":"6","key":"1769_CR194","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"1769_CR195","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015346","author":"A Riedel","year":"2025","unstructured":"Riedel A, Phely L, Hug S, Faustmann P, Schr\u00f6der J, Besemer B, et al. Immunological consequences of CAR T-Cell Therapy - Analysis of infectious complications and immune reconstitution. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2024015346.","journal-title":"Blood Adv"},{"key":"1769_CR196","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","author":"R Kansal","year":"2019","unstructured":"Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aav1648.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1769_CR197","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","volume":"25","author":"S Minguet","year":"2024","unstructured":"Minguet S, Maus MV, Schamel WW. From TCR fundamental research to innovative chimeric antigen receptor design. Nat Rev Immunol. 2024;25(3):212\u201324. https:\/\/doi.org\/10.1038\/s41577-024-01093-7.","journal-title":"Nat Rev Immunol"},{"key":"1769_CR198","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.19462.","journal-title":"JAMA"},{"key":"1769_CR199","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05772-5","author":"L Kattamuri","year":"2025","unstructured":"Kattamuri L, Mohan Lal B, Vojjala N, Jain M, Sharma K, Jain S, et al. Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review. Rheumatol Int. 2025. https:\/\/doi.org\/10.1007\/s00296-024-05772-5.","journal-title":"Rheumatol Int"},{"issue":"9","key":"1769_CR200","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","volume":"50","author":"T Schroeder","year":"2024","unstructured":"Schroeder T, Martens T, Fransecky L, Valerius T, Schub N, Pott C, et al. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities. Intensive Care Med. 2024;50(9):1459\u201369. https:\/\/doi.org\/10.1007\/s00134-024-07576-4.","journal-title":"Intensive Care Med"},{"key":"1769_CR201","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00490-x","author":"Z Liu","year":"2024","unstructured":"Liu Z, Lei W, Wang H, Liu X, Fu R. Challenges and strategies associated with CAR-T cell therapy in blood malignancies. Exp Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s40164-024-00490-x.","journal-title":"Exp Hematol Oncol"},{"key":"1769_CR202","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315898120","author":"S Kang","year":"2024","unstructured":"Kang S, Onishi S, Ling Z, Inoue H, Zhang Y, Chang H, et al. Gp130\u2013HIF1\u03b1 axis\u2013induced vascular damage is prevented by the short-term inhibition of IL-6 receptor signaling. Proc Natl Acad Sci U S A. 2024. https:\/\/doi.org\/10.1073\/pnas.2315898120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1769_CR203","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.cd-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.cd-17-1319.","journal-title":"Cancer Discov"},{"issue":"Supplement 1","key":"1769_CR204","doi-asserted-by":"publisher","first-page":"10335","DOI":"10.1182\/blood-2022-169265","volume":"140","author":"J Feng","year":"2022","unstructured":"Feng J, Hu Y, Zhang M, Cao H, Ke Y, Xu H, et al. Safety and efficacy of CD19 CAR-T cells for refractory systemic sclerosis: a phase I clinical trial. Blood. 2022;140(Supplement 1):10335\u20136. https:\/\/doi.org\/10.1182\/blood-2022-169265.","journal-title":"Blood"},{"issue":"1","key":"1769_CR205","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","volume":"60","author":"A Rampotas","year":"2024","unstructured":"Rampotas A, Richter J, Isenberg D, Roddie C. CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transplant. 2024;60(1):6\u20139. https:\/\/doi.org\/10.1038\/s41409-024-02429-6.","journal-title":"Bone Marrow Transplant"},{"key":"1769_CR206","doi-asserted-by":"publisher","unstructured":"Gutierrez DB, Santurio DS, Barros LRC, Glauche I, Fassoni Ac. Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome. PLoS Comput Biol. 2025;21(4). https:\/\/doi.org\/10.1371\/journal.pcbi.1012908.","DOI":"10.1371\/journal.pcbi.1012908"},{"issue":"3","key":"1769_CR207","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jtct.2025.01.001","volume":"31","author":"E Abadir","year":"2025","unstructured":"Abadir E, Wayte R, Li W, Gupta S, Yang S, Reaiche E, et al. Reduced chimeric antigen receptor T cell expansion postinfusion is associated with poor survival in patients with large B cell lymphoma after two or more therapies. Transplantation Cell Therapy. 2025;31(3):159\u201365. https:\/\/doi.org\/10.1016\/j.jtct.2025.01.001.","journal-title":"Transplantation Cell Therapy"},{"issue":"6","key":"1769_CR208","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","volume":"17","author":"W Zhang","year":"2021","unstructured":"Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q, et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR. Stem Cell Reviews Rep. 2021;17(6):2120\u20133. https:\/\/doi.org\/10.1007\/s12015-021-10251-6.","journal-title":"Stem Cell Reviews Rep"},{"key":"1769_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01471-y","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023. https:\/\/doi.org\/10.1038\/s41392-023-01471-y.","journal-title":"Signal Transduct Target Ther"},{"key":"1769_CR210","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1166135","author":"JA Bluestone","year":"2023","unstructured":"Bluestone JA, McKenzie BS, Beilke J, Ramsdell F. Opportunities for Treg cell therapy for the treatment of human disease. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1166135.","journal-title":"Front Immunol"},{"issue":"10","key":"1769_CR211","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/cm9.0000000000003111","volume":"137","author":"Y Liu","year":"2024","unstructured":"Liu Y, Dong M, Chu Y, Zhou L, You Y, Pang X, et al. Dawn of CAR-T cell therapy in autoimmune diseases. Chin Med J. 2024;137(10):1140\u201350. https:\/\/doi.org\/10.1097\/cm9.0000000000003111.","journal-title":"Chin Med J"},{"issue":"10188","key":"1769_CR212","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/s0140-6736(19)30237-5","volume":"393","author":"L Durcan","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332\u201343. https:\/\/doi.org\/10.1016\/s0140-6736(19)30237-5.","journal-title":"Lancet"},{"key":"1769_CR213","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133168","author":"B Ca\u00ebl","year":"2022","unstructured":"Ca\u00ebl B, Galaine J, Bardey I, Marton C, Fredon M, Biichle S, et al. Umbilical cord blood as a source of less differentiated T cells to produce CD123 CAR-T cells. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14133168.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"1769_CR214","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1016\/j.ymthe.2024.06.022","volume":"32","author":"CR Maldini","year":"2024","unstructured":"Maldini CR, Messana AC, Bendet PB, Camblin AJ, Musenge FM, White ML, et al. Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells. Mol Ther. 2024;32(10):3485\u2013503. https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.022.","journal-title":"Mol Ther"},{"issue":"22","key":"1769_CR215","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","volume":"3","author":"V Pillai","year":"2019","unstructured":"Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):3539\u201349. https:\/\/doi.org\/10.1182\/bloodadvances.2019000692.","journal-title":"Blood Adv"},{"key":"1769_CR216","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0280-y","author":"S Liu","year":"2020","unstructured":"Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020. https:\/\/doi.org\/10.1038\/s41408-020-0280-y.","journal-title":"Blood Cancer J"},{"issue":"10","key":"1769_CR217","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.ymthe.2024.08.025","volume":"32","author":"L Amini","year":"2024","unstructured":"Amini L, Peter L, Schmueck-Henneresse M. Engineering a solution for allogeneic CAR-T rejection. Mol Ther. 2024;32(10):3204\u20136. https:\/\/doi.org\/10.1016\/j.ymthe.2024.08.025.","journal-title":"Mol Ther"},{"issue":"4","key":"1769_CR218","doi-asserted-by":"publisher","first-page":"S798","DOI":"10.3945\/an.115.011221","volume":"7","author":"EA Ananieva","year":"2016","unstructured":"Ananieva EA, Powell JD, Hutson SM. Leucine metabolism in T cell activation: mTOR signaling and beyond. Adv Nutr. 2016;7(4):S798\u2013805. https:\/\/doi.org\/10.3945\/an.115.011221.","journal-title":"Adv Nutr"},{"issue":"1","key":"1769_CR219","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"key":"1769_CR220","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01745-8","author":"J Su","year":"2025","unstructured":"Su J, Zeng Y, Song Z, Liu Y, Ou K, Wu Y, et al. Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies. J Hematol Oncol. 2025. https:\/\/doi.org\/10.1186\/s13045-025-01745-8.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1769_CR221","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41422-025-01128-1","volume":"35","author":"C Yang","year":"2025","unstructured":"Yang C, Sun C, Tan B, Hu C, Wan L, Wang C, et al. Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus. Cell Res. 2025;35(8):607\u20139. https:\/\/doi.org\/10.1038\/s41422-025-01128-1.","journal-title":"Cell Res"},{"issue":"9","key":"1769_CR222","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.stem.2025.07.009","volume":"32","author":"X Hu","year":"2025","unstructured":"Hu X, Beauchesne P, Wang C, Wong A, Deuse T, Schrepfer S. Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease. Cell Stem Cell. 2025;32(9):1356-1368.e1354. https:\/\/doi.org\/10.1016\/j.stem.2025.07.009.","journal-title":"Cell Stem Cell"},{"key":"1769_CR223","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191912366","author":"G Choi","year":"2022","unstructured":"Choi G, Shin G, Bae S. Price and prejudice? The value of chimeric antigen receptor (CAR) T-cell therapy. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph191912366.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"1769_CR224","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","volume":"7","author":"KC Potnis","year":"2023","unstructured":"Potnis KC, Di M, Isufi I, Gowda L, Seropian SE, Foss FM, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv. 2023;7(5):801\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2022008097.","journal-title":"Blood Adv"},{"key":"1769_CR225","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae359","author":"M Kanbay","year":"2025","unstructured":"Kanbay M, Mizrak B, Alper EN, Copur S, Ortiz A. Acute kidney injury following CAR-T cell therapy: a nephrologist\u2019s perspective. Clin Kidney J. 2025. https:\/\/doi.org\/10.1093\/ckj\/sfae359.","journal-title":"Clin Kidney J"},{"issue":"3","key":"1769_CR226","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s44228-022-00004-8","volume":"4","author":"R Ellard","year":"2022","unstructured":"Ellard R, Kenyon M, Hutt D, Aerts E, de Ruijter M, Chabannon C, et al. The EBMT immune effector cell nursing guidelines on CAR-T therapy: a framework for patient care and managing common toxicities. Clin Hematol Int. 2022;4(3):75\u201388. https:\/\/doi.org\/10.1007\/s44228-022-00004-8.","journal-title":"Clin Hematol Int"},{"issue":"3","key":"1769_CR227","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33(3):259\u201375. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.003.","journal-title":"Ann Oncol"},{"issue":"1","key":"1769_CR228","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae S-C, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762.","journal-title":"Ann Rheum Dis"},{"key":"1769_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102476","author":"R Greco","year":"2024","unstructured":"Greco R, Alexander T, Del Papa N, M\u00fcller F, Saccardi R, Sanchez-Guijo F, et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. Eclin Med. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102476.","journal-title":"Eclin Med"},{"issue":"5","key":"1769_CR230","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41584-019-0214-x","volume":"15","author":"J McHugh","year":"2019","unstructured":"McHugh J. CAR T cells drive out B cells in SLE. Nat Rev Rheumatol. 2019;15(5):249\u2013249. https:\/\/doi.org\/10.1038\/s41584-019-0214-x.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1769_CR231","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.4049\/jimmunol.1500792","volume":"195","author":"JR Giles","year":"2015","unstructured":"Giles JR, Kashgarian M, Koni PA, Shlomchik MJ. B cell\u2013specific MHC class II deletion reveals multiple nonredundant roles for B cell antigen presentation in murine lupus. J Immunol. 2015;195(6):2571\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1500792.","journal-title":"J Immunol"},{"issue":"8","key":"1769_CR232","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2020","unstructured":"Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2020;18(8):1896\u2013903. https:\/\/doi.org\/10.1038\/s41423-020-0472-1.","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"1769_CR233","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/rheumatology\/38.8.757","volume":"38","author":"DW van Bekkum","year":"1999","unstructured":"van Bekkum DW. Effectiveness and risks of total body irradiation for conditioning in the treatment of autoimmune disease with autologous bone marrow transplantation. Rheumatology. 1999;38(8):757\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/38.8.757.","journal-title":"Rheumatology"},{"issue":"11","key":"1769_CR234","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/acr2.11614","volume":"5","author":"A Boulougoura","year":"2023","unstructured":"Boulougoura A, Gendelman H, Surmachevska N, Kyttaris VC. Journal club: anti-CD19 chimeric antigen receptor T cell therapy for refractory systemic lupus erythematosus. ACR Open Rheumatol. 2023;5(11):624\u20138. https:\/\/doi.org\/10.1002\/acr2.11614.","journal-title":"ACR Open Rheumatol"},{"issue":"10","key":"1769_CR235","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41584-021-00691-2","volume":"17","author":"S Onuora","year":"2021","unstructured":"Onuora S. CAR T cells induce remission in a patient with refractory SLE. Nat Rev Rheumatol. 2021;17(10):579\u2013579. https:\/\/doi.org\/10.1038\/s41584-021-00691-2.","journal-title":"Nat Rev Rheumatol"},{"key":"1769_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(24)00098-5","author":"T Burki","year":"2024","unstructured":"Burki T. CAR T-cell therapy for SLE in children. Lancet Rheumatol. 2024. https:\/\/doi.org\/10.1016\/s2665-9913(24)00098-5.","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"1769_CR237","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41584-022-00865-6","volume":"18","author":"R Phillips","year":"2022","unstructured":"Phillips R. CAR T cells induce drug-free SLE remission. Nat Rev Rheumatol. 2022;18(12):671\u2013671. https:\/\/doi.org\/10.1038\/s41584-022-00865-6.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"1769_CR238","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1056\/NEJMc2403743","volume":"391","author":"M Li","year":"2024","unstructured":"Li M, Zhang Y, Jiang N, Ning C, Wang Q, Xu D, et al. Anti\u2013CD19 CAR T cells in refractory immune thrombocytopenia of SLE. N Engl J Med. 2024;391(4):376\u20138. https:\/\/doi.org\/10.1056\/NEJMc2403743.","journal-title":"N Engl J Med"},{"key":"1769_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.08.023","author":"D Nunez","year":"2023","unstructured":"Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, M\u00fcller F, et al. Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy. Molecular Therapy - Methods & Clinical Development. 2023. https:\/\/doi.org\/10.1016\/j.omtm.2023.08.023.","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"key":"1769_CR240","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017414","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN, How I, Treat Refractory CRS. ICANS following CAR T-cell therapy. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2022017414.","journal-title":"Blood"},{"issue":"5","key":"1769_CR241","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/cm9.0000000000003406","volume":"138","author":"Y Wang","year":"2024","unstructured":"Wang Y, Lu L, Ye S, Fu Q. CAR-based cell therapies for systemic lupus erythematosus. Chin Med J. 2024;138(5):523\u201330. https:\/\/doi.org\/10.1097\/cm9.0000000000003406.","journal-title":"Chin Med J"},{"issue":"3","key":"1769_CR242","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","volume":"84","author":"I Minopoulou","year":"2025","unstructured":"Minopoulou I, Wilhelm A, Albach F, Kleyer A, Wiebe E, Schallenberg S, et al. Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis. Ann Rheum Dis. 2025;84(3):e4\u20137. https:\/\/doi.org\/10.1016\/j.ard.2025.01.008.","journal-title":"Ann Rheum Dis"},{"key":"1769_CR243","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1502712","author":"C Rangel-Pel\u00e1ez","year":"2024","unstructured":"Rangel-Pel\u00e1ez C, Mart\u00ednez-Guti\u00e9rrez L, Trist\u00e1n-Manzano M, Callejas JL, Ortego-Centeno N, Mart\u00edn F, et al. CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases? Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1502712.","journal-title":"Front Immunol"},{"issue":"10416","key":"1769_CR244","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/s0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402(10416):2034\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(23)01126-1.","journal-title":"Lancet"},{"issue":"2","key":"1769_CR245","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","volume":"80","author":"B Zhang","year":"2021","unstructured":"Zhang B, Wang Y, Yuan Y, Sun J, Liu L, Huang D, et al. In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells. Ann Rheum Dis. 2021;80(2):176\u201384. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217844.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1769_CR246","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/ard-2024-226437","volume":"84","author":"M Lidar","year":"2025","unstructured":"Lidar M, Rimar D, David P, Jacoby E, Shapira-Frommer R, Itzhaki O, et al. CD-19 CAR-T cells for polyrefractory rheumatoid arthritis. Ann Rheum Dis. 2025;84(2):370\u20132. https:\/\/doi.org\/10.1136\/ard-2024-226437.","journal-title":"Ann Rheum Dis"},{"key":"1769_CR247","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf077","author":"FN Albach","year":"2025","unstructured":"Albach FN, Minopoulou I, Wilhelm A, Biesen R, Kleyer A, Wiebe E, et al. Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology. 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf077.","journal-title":"Rheumatology"},{"key":"1769_CR248","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004727","author":"D Szabo","year":"2024","unstructured":"Szabo D, Balogh A, Gopcsa L, Giba-Kiss L, Lakatos G, Paksi M, et al. Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2024-004727.","journal-title":"RMD Open"},{"issue":"3","key":"1769_CR249","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","volume":"35","author":"Y Li","year":"2025","unstructured":"Li Y, Li S, Zhao X, Sheng J, Xue L, Schett G, et al. Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis. Cell Res. 2025;35(3):220\u20133. https:\/\/doi.org\/10.1038\/s41422-024-01068-2.","journal-title":"Cell Res"},{"key":"1769_CR250","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.14236","author":"R Marcus","year":"2022","unstructured":"Marcus R. What is Multiple Sclerosis? JAMA. 2022. https:\/\/doi.org\/10.1001\/jama.2022.14236.","journal-title":"JAMA"},{"issue":"6","key":"1769_CR251","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.medj.2024.04.005","volume":"5","author":"AW Rankin","year":"2024","unstructured":"Rankin AW, Shah NN. CD19 CAR T cells for multiple sclerosis: forging further into the new frontier. Med. 2024;5(6):482\u20134. https:\/\/doi.org\/10.1016\/j.medj.2024.04.005.","journal-title":"Med"},{"key":"1769_CR252","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200080","author":"S Gupta","year":"2023","unstructured":"Gupta S, Simic M, Sagan SA, Shepherd C, Duecker J, Sobel RA, et al. CAR-T cell\u2013mediated B-cell depletion in central nervous system autoimmunity. Neurology Neuroimmunology & Neuroinflammation. 2023. https:\/\/doi.org\/10.1212\/nxi.0000000000200080.","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"key":"1769_CR253","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-00470-5","author":"A Mullard","year":"2024","unstructured":"Mullard A. CAR-T therapy for multiple sclerosis enters US trials for first time. Nature. 2024. https:\/\/doi.org\/10.1038\/d41586-024-00470-5.","journal-title":"Nature"},{"issue":"6","key":"1769_CR254","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/brain\/awn077","volume":"131","author":"M Krumbholz","year":"2008","unstructured":"Krumbholz M, Faber H, Steinmeyer F, Hoffmann LA, K\u00fcmpfel T, Pellkofer H, et al. Interferon-\u03b2 increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain. 2008;131(6):1455\u201363. https:\/\/doi.org\/10.1093\/brain\/awn077.","journal-title":"Brain"},{"key":"1769_CR255","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16174","author":"C Sales","year":"2023","unstructured":"Sales C, Anderson MA, Kuznetsova V, Rosenfeld H, Malpas CB, Roos I, et al. Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: a single\u2010centre cohort study. Eur J Neurol. 2023. https:\/\/doi.org\/10.1111\/ene.16174.","journal-title":"Eur J Neurol"},{"issue":"7","key":"1769_CR256","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1902226.","journal-title":"N Engl J Med"},{"key":"1769_CR257","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100097","author":"H Ma","year":"2020","unstructured":"Ma H, Jeppesen JF, Jaenisch R. Human T cells expressing a CD19 CAR-T receptor provide insights into mechanisms of human CD19-positive \u03b2 cell destruction. Cell Rep Med. 2020. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100097.","journal-title":"Cell Rep Med"},{"key":"1769_CR258","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","volume":"96","author":"L Zhang","year":"2019","unstructured":"Zhang L, Sosinowski T, Cox AR, Cepeda JR, Sekhar NS, Hartig SM, et al. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes. J Autoimmun. 2019;96:50\u20138. https:\/\/doi.org\/10.1016\/j.jaut.2018.08.004.","journal-title":"J Autoimmun"},{"key":"1769_CR259","doi-asserted-by":"publisher","unstructured":"Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7(315). https:\/\/doi.org\/10.1126\/scitranslmed.aad4134.","DOI":"10.1126\/scitranslmed.aad4134"},{"issue":"9","key":"1769_CR260","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/ajt.17063","volume":"22","author":"JC Wagner","year":"2022","unstructured":"Wagner JC, Ronin E, Ho P, Peng Y, Tang Q. Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival. Am J Transplant. 2022;22(9):2237\u201345. https:\/\/doi.org\/10.1111\/ajt.17063.","journal-title":"Am J Transplant"},{"key":"1769_CR261","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101385","author":"RW Cochrane","year":"2024","unstructured":"Cochrane RW, Robino RA, Granger B, Allen E, Vaena S, Romeo MJ, et al. High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells. Mol Ther Methods Clin Dev. 2024. https:\/\/doi.org\/10.1016\/j.omtm.2024.101385.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1769_CR262","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.171844","author":"GI Uenishi","year":"2024","unstructured":"Uenishi GI, Repic M, Yam JY, Landuyt A, Saikumar-Lakshmi P, Guo T, et al. GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes. JCI Insight. 2024. https:\/\/doi.org\/10.1172\/jci.insight.171844.","journal-title":"JCI Insight"},{"issue":"2","key":"1769_CR263","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2018;15(2):113\u201324. https:\/\/doi.org\/10.1038\/s41582-018-0110-z.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"1769_CR264","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","volume":"32","author":"J Volkov","year":"2024","unstructured":"Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z, et al. Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial. Mol Ther. 2024;32(11):3821\u20138. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.009.","journal-title":"Mol Ther"},{"issue":"11","key":"1769_CR265","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJW, Sievers SA, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25(11):2452\u201365. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.013.","journal-title":"Mol Ther"},{"key":"1769_CR266","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239163","author":"CH Kang","year":"2020","unstructured":"Kang CH, Kim Y, Lee HK, Lee SM, Jeong HG, Choi SU, et al. Identification of potent CD19 scFv for CAR T cells through scFv screening with NK\/T-cell line. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21239163.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1769_CR267","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","volume":"25","author":"E Drent","year":"2017","unstructured":"Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, et al. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther. 2017;25(8):1946\u201358. https:\/\/doi.org\/10.1016\/j.ymthe.2017.04.024.","journal-title":"Mol Ther"},{"key":"1769_CR268","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.32","author":"Z Grada","year":"2013","unstructured":"Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013. https:\/\/doi.org\/10.1038\/mtna.2013.32.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1769_CR269","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1407992","author":"AM Alviano","year":"2024","unstructured":"Alviano AM, Biondi M, Grassenis E, Biondi A, Serafini M, Tettamanti S. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1407992.","journal-title":"Front Immunol"},{"issue":"4","key":"1769_CR270","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/cas.14799","volume":"112","author":"Z Guo","year":"2021","unstructured":"Guo Z, Tu S, Yu S, Wu L, Pan W, Chang N, et al. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. Cancer Sci. 2021;112(4):1357\u201368. https:\/\/doi.org\/10.1111\/cas.14799.","journal-title":"Cancer Sci"},{"issue":"3","key":"1769_CR271","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145\u201361. https:\/\/doi.org\/10.1038\/s41568-020-00323-z.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1769_CR272","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/2326-6066.cir-19-0908","volume":"8","author":"D Wijewarnasuriya","year":"2020","unstructured":"Wijewarnasuriya D, Bebernitz C, Lopez AV, Rafiq S, Brentjens RJ. Excessive costimulation leads to dysfunction of adoptively transferred T cells. Cancer Immunol Res. 2020;8(6):732\u201342. https:\/\/doi.org\/10.1158\/2326-6066.cir-19-0908.","journal-title":"Cancer Immunol Res"},{"key":"1769_CR273","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16679","author":"K Abulikemu","year":"2023","unstructured":"Abulikemu K, Hu F, Liang J, Kang X. Targeting therapy in pemphigus: where are we now and where are we going? Heliyon. 2023. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16679.","journal-title":"Heliyon"},{"key":"1769_CR274","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012. https:\/\/doi.org\/10.1186\/2162-3619-1-36.","journal-title":"Exp Hematol Oncol"},{"key":"1769_CR275","doi-asserted-by":"publisher","DOI":"10.1186\/ar3909","author":"HE Mei","year":"2012","unstructured":"Mei HE, Schmidt S, D\u00f6rner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther. 2012. https:\/\/doi.org\/10.1186\/ar3909.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1769_CR276","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard-2023-224827","volume":"83","author":"TI Papadimitriou","year":"2024","unstructured":"Papadimitriou TI, Singh P, van Caam A, Walgreen B, Gorris MAJ, Vitters EL, et al. CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for selective cell depletion. Ann Rheum Dis. 2024;83(4):488\u201398. https:\/\/doi.org\/10.1136\/ard-2023-224827.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1769_CR277","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/2772270817666221122103029","volume":"17","author":"S Desai","year":"2023","unstructured":"Desai S, Kashalikar P, Sanap A, Shekatkar M, Bhonde R. Narrative review of anti-CD3 antibody and anti-CD20 antibody: immunotherapeutic strategies to treat and prevent type 1 diabetes. Recent Adv Inflamm Allergy Drug Discov. 2023;17(1):64\u201370. https:\/\/doi.org\/10.2174\/2772270817666221122103029.","journal-title":"Recent Adv Inflamm Allergy Drug Discov"},{"key":"1769_CR278","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.595547","author":"CA Roach","year":"2021","unstructured":"Roach CA, Cross AH. Anti-CD20 B cell treatment for relapsing multiple sclerosis. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/fneur.2020.595547.","journal-title":"Front Neurol"},{"key":"1769_CR279","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119853","author":"X Zhu","year":"2021","unstructured":"Zhu X, Bian F, Zhao Y, Qin Y, Sun X, Zhou L. WITHDRAWN: combined therapy of adenovirus vector mediated IGF-1 gene with anti-CD20 mAbs exerts potential beneficial role on type 1 diabetes in Nonobese diabetic mice. Life Sci. 2021. https:\/\/doi.org\/10.1016\/j.lfs.2021.119853.","journal-title":"Life Sci"},{"issue":"25","key":"1769_CR280","doi-asserted-by":"publisher","first-page":"16971","DOI":"10.1074\/jbc.M708459200","volume":"283","author":"CA Walshe","year":"2008","unstructured":"Walshe CA, Beers SA, French RR, Chan CHT, Johnson PW, Packham GK, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem. 2008;283(25):16971\u201384. https:\/\/doi.org\/10.1074\/jbc.M708459200.","journal-title":"J Biol Chem"},{"key":"1769_CR281","doi-asserted-by":"publisher","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A, Laplaud DA, Michel L, Thouvenot E, et al. Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1004795.","DOI":"10.3389\/fimmu.2023.1004795"},{"issue":"8","key":"1769_CR282","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, et al. A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood. 2014;124(8):1277\u201387. https:\/\/doi.org\/10.1182\/blood-2014-01-545020.","journal-title":"Blood"},{"issue":"1","key":"1769_CR283","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920.","journal-title":"Ann Rheum Dis"},{"key":"1769_CR284","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03937-8","author":"J Feng","year":"2025","unstructured":"Feng J, Huo D, Hong R, Jin X, Cao H, Shao M, et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03937-8.","journal-title":"Nat Med"},{"issue":"12","key":"1769_CR285","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1056\/NEJMc2508023","volume":"393","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Atreya R, V\u00f6lkl S, Aigner M, Kretschmann S, Kharboutli S, et al. CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis. N Engl J Med. 2025;393(12):1239\u201341. https:\/\/doi.org\/10.1056\/NEJMc2508023.","journal-title":"N Engl J Med"},{"key":"1769_CR286","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03899-x","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Wang H, Wu X, He C, Lin S, et al. Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03899-x.","journal-title":"Nat Med"},{"issue":"3","key":"1769_CR287","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M, Seidel K, Huang W, Rawlings-Rhea SD, et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic Pontine glioma: a phase 1 trial. Nat Med. 2025;31(3):861\u20138. https:\/\/doi.org\/10.1038\/s41591-024-03451-3.","journal-title":"Nat Med"},{"key":"1769_CR288","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01075-5","author":"JPW Heidbuechel","year":"2021","unstructured":"Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol. 2021. https:\/\/doi.org\/10.1186\/s13045-021-01075-5.","journal-title":"J Hematol Oncol"},{"issue":"17","key":"1769_CR289","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.can-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697\u2013706. https:\/\/doi.org\/10.1158\/0008-5472.can-11-0103.","journal-title":"Cancer Res"},{"key":"1769_CR290","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1141880","author":"R Wakao","year":"2023","unstructured":"Wakao R, Fukaya-Shiba A. In vivo CAR T cells and targeted gene delivery: a theme for the Pharmaceuticals and Medical Devices Agency Science Board to address. Front Med. 2023. https:\/\/doi.org\/10.3389\/fmed.2023.1141880.","journal-title":"Front Med"},{"key":"1769_CR291","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.809754","author":"T Xin","year":"2022","unstructured":"Xin T, Cheng L, Zhou C, Zhao Y, Hu Z, Wu X. In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.809754.","journal-title":"Front Oncol"},{"key":"1769_CR292","doi-asserted-by":"publisher","unstructured":"Fedorov VD, Themeli M, Sadelain M. PD-1\u2013 and CTLA-4\u2013Based inhibitory chimeric antigen receptors (iCARs) divert Off-Target immunotherapy responses. Sci Transl Med. 2013;5(215). https:\/\/doi.org\/10.1126\/scitranslmed.3006597.","DOI":"10.1126\/scitranslmed.3006597"},{"key":"1769_CR293","doi-asserted-by":"publisher","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591). https:\/\/doi.org\/10.1126\/scitranslmed.abe7378.","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"1769_CR294","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, et al. Synnotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.abd8836.","journal-title":"Sci Transl Med"},{"key":"1769_CR295","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101070","author":"E Moghanloo","year":"2021","unstructured":"Moghanloo E, Mollanoori H, Talebi M, Pashangzadeh S, Faraji F, Hadjilooei F, et al. Remote controlling of CAR-T cells and toxicity management: molecular switches and next generation CARs. Transl Oncol. 2021. https:\/\/doi.org\/10.1016\/j.tranon.2021.101070.","journal-title":"Transl Oncol"},{"key":"1769_CR296","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6295","author":"M Jan","year":"2021","unstructured":"Jan M, Scarf\u00f2 I, Larson RC, Walker A, Schmidts A, Guirguis AA, et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.abb6295.","journal-title":"Sci Transl Med"},{"issue":"9","key":"1769_CR297","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2326-6066.cir-21-0095","volume":"9","author":"AC Sahillioglu","year":"2021","unstructured":"Sahillioglu AC, Toebes M, Apriamashvili G, Gomez R, Schumacher TN. CRASH-IT switch enables reversible and Dose-Dependent control of TCR and CAR T-cell function. Cancer Immunol Res. 2021;9(9):999\u20131007. https:\/\/doi.org\/10.1158\/2326-6066.cir-21-0095.","journal-title":"Cancer Immunol Res"},{"key":"1769_CR298","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01625-7","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang l, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s13045-024-01625-7.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1769_CR299","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","volume":"30","author":"A Michels","year":"2022","unstructured":"Michels A, Ho N, Buchholz CJ. Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms. Mol Ther. 2022;30(7):2401\u201315. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.018.","journal-title":"Mol Ther"},{"key":"1769_CR300","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.omto.2022.04.008","volume":"25","author":"D Cao","year":"2022","unstructured":"Cao D, Song Q, Li J, Chard Dunmall LS, Jiang Y, Qin B, et al. Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene. Mol Ther Oncolytics. 2022;25:264\u201375. https:\/\/doi.org\/10.1016\/j.omto.2022.04.008.","journal-title":"Mol Ther Oncolytics"},{"key":"1769_CR301","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01574-1","author":"Z Cheng","year":"2024","unstructured":"Cheng Z, Fobian S-F, Gurrieri E, Amin M, D\u2019Agostino VG, Falahati M, et al. Lipid-based nanosystems: the next generation of cancer immune therapy. J Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s13045-024-01574-1.","journal-title":"J Hematol Oncol"},{"key":"1769_CR302","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"J-e Zhou","year":"2022","unstructured":"Zhou J-e, Sun L, Jia Y, Wang Z, Luo T, Tan J, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.033.","journal-title":"J Control Release"},{"key":"1769_CR303","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01408-5","author":"S Wang","year":"2023","unstructured":"Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023. https:\/\/doi.org\/10.1038\/s41392-023-01408-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1769_CR304","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/cas.13892","volume":"110","author":"S Iriguchi","year":"2019","unstructured":"Iriguchi S, Kaneko S. Toward the development of true off-the\u2010shelf synthetic T\u2010cell immunotherapy. Cancer Sci. 2019;110(1):16\u201322. https:\/\/doi.org\/10.1111\/cas.13892.","journal-title":"Cancer Sci"},{"issue":"10","key":"1769_CR305","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","volume":"31","author":"M Themeli","year":"2013","unstructured":"Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31(10):928\u201333. https:\/\/doi.org\/10.1038\/nbt.2678.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1769_CR306","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang Z, McWilliams-Koeppen HP, Reza H, Ostberg JR, Chen W, Wang X, et al. 3D-organoid culture supports differentiation of human CAR\u2009+\u2009iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022;29(4):515\u2013e527518. https:\/\/doi.org\/10.1016\/j.stem.2022.02.009.","journal-title":"Cell Stem Cell"},{"key":"1769_CR307","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0677-2","author":"J Zhao","year":"2018","unstructured":"Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018. https:\/\/doi.org\/10.1186\/s13045-018-0677-2.","journal-title":"J Hematol Oncol"},{"key":"1769_CR308","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1052717","author":"W Li","year":"2022","unstructured":"Li W, Zhu X, Xu Y, Chen J, Zhang H, Yang Z, et al. Simultaneous editing of TCR, HLA-I\/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.1052717.","journal-title":"Front Immunol"},{"key":"1769_CR309","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020023","author":"F del Bufalo","year":"2023","unstructured":"del Bufalo F, Becilli M, Rosignoli C, De Angelis B, Algeri M, Hanssens L, et al. Allogeneic, donor-derived, second-generation, CD19-CAR-T cell for the treatment of pediatric relapsed\/refractory BCP-ALL. Blood J. 2023. https:\/\/doi.org\/10.1182\/blood.2023020023.","journal-title":"Blood J"},{"key":"1769_CR310","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2024.010","author":"U Testa","year":"2024","unstructured":"Testa U, Sica S, Pelosi E, Castelli G, Leone G. Car-T cell therapy in B-cell acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2024. https:\/\/doi.org\/10.4084\/mjhid.2024.010.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"11","key":"1769_CR311","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1158\/2767-9764.crc-22-0176","volume":"2","author":"T Derippe","year":"2022","unstructured":"Derippe T, Fouliard S, Marchiq I, Dupouy S, Almena-Carrasco M, Geronimi J, et al. Mechanistic modeling of the interplay between host immune system, IL-7 and UCART19 allogeneic CAR-T cells in adult B-cell acute lymphoblastic leukemia. Cancer Res Commun. 2022;2(11):1532\u201344. https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0176.","journal-title":"Cancer Res Commun"},{"key":"1769_CR312","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071684","author":"F Korell","year":"2021","unstructured":"Korell F, Schubert M-L, Sauer T, Schmitt A, Derigs P, Weber TF, et al. Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed\/refractory acute lymphoblastic leukemia or B cell non-Hodgkin lymphoma. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13071684.","journal-title":"Cancers"},{"issue":"15","key":"1769_CR313","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang Q, Xiao ZX, Zheng X, Wang G, Yang L, Shi L, et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N Engl J Med. 2025;393(15):1542\u20134. https:\/\/doi.org\/10.1056\/NEJMc2509522.","journal-title":"N Engl J Med"},{"issue":"9","key":"1769_CR314","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai CJ, Parker MH, Qin J, Tang W, Ulrich-Lewis JT, Gottschalk RJ, et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood. 2024;144(9):977\u201387. https:\/\/doi.org\/10.1182\/blood.2024024523.","journal-title":"Blood"},{"key":"1769_CR315","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01246-y","author":"Z Sun","year":"2022","unstructured":"Sun Z, Li R, Shen Y, Tan S, Ding N, Xu R, et al. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors. J Hematol Oncol. 2022. https:\/\/doi.org\/10.1186\/s13045-022-01246-y.","journal-title":"J Hematol Oncol"},{"key":"1769_CR316","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301515","author":"AG Hamilton","year":"2023","unstructured":"Hamilton AG, Swingle KL, Joseph RA, Mai D, Gong N, Billingsley MM, et al. Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA CAR T cell engineering. Adv Healthc Mater. 2023. https:\/\/doi.org\/10.1002\/adhm.202301515.","journal-title":"Adv Healthc Mater"},{"key":"1769_CR317","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.106084","author":"R Zhang","year":"2022","unstructured":"Zhang R, Han X, Lei Z, Jiang C, Gul I, Hu Q, et al. RCMNet: a deep learning model assists CAR-T therapy for leukemia. Comput Biol Med. 2022. https:\/\/doi.org\/10.1016\/j.compbiomed.2022.106084.","journal-title":"Comput Biol Med"},{"key":"1769_CR318","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00602-z","author":"P Song","year":"2024","unstructured":"Song P, Zhang Q, Xu Z, Shi Y, Jing R, Luo D. CRISPR\/Cas-based CAR-T cells: production and application. Biomark Res. 2024. https:\/\/doi.org\/10.1186\/s40364-024-00602-z.","journal-title":"Biomark Res"},{"key":"1769_CR319","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00482-9","author":"M Mazinani","year":"2023","unstructured":"Mazinani M, Rahbarizadeh F. New cell sources for CAR-based immunotherapy. Biomark Res. 2023. https:\/\/doi.org\/10.1186\/s40364-023-00482-9.","journal-title":"Biomark Res"},{"issue":"7","key":"1769_CR320","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/1744666x.2019.1620602","volume":"15","author":"M Ryba-Stanis\u0142awowska","year":"2019","unstructured":"Ryba-Stanis\u0142awowska M, Sakowska J, Zieli\u0144ski M, \u0141awrynowicz U, Trzonkowski P. Regulatory T cells: the future of autoimmune disease treatment. Expert Rev Clin Immunol. 2019;15(7):777\u201389. https:\/\/doi.org\/10.1080\/1744666x.2019.1620602.","journal-title":"Expert Rev Clin Immunol"},{"key":"1769_CR321","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.565518","author":"LV Terry","year":"2020","unstructured":"Terry LV, Oo YH. The next frontier of regulatory T cells: promising immunotherapy for autoimmune diseases and organ transplantations. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.565518.","journal-title":"Front Immunol"},{"key":"1769_CR322","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126194","author":"AC Boroughs","year":"2019","unstructured":"Boroughs AC, Larson RC, Choi BD, Bouffard AA, Riley LS, Schiferle E, et al. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.126194.","journal-title":"JCI Insight"},{"key":"1769_CR323","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46448-9","author":"M Doglio","year":"2024","unstructured":"Doglio M, Ugolini A, Bercher-Brayer C, Camisa B, Toma C, Norata R, et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-46448-9.","journal-title":"Nat Commun"},{"key":"1769_CR324","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103057","author":"P Henschel","year":"2023","unstructured":"Henschel P, Landwehr-Kenzel S, Engels N, Schienke A, Kremer J, Riet T, et al. Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application. J Autoimmun. 2023. https:\/\/doi.org\/10.1016\/j.jaut.2023.103057.","journal-title":"J Autoimmun"},{"key":"1769_CR325","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03262-w","author":"J Frikeche","year":"2024","unstructured":"Frikeche J, David M, Mouska X, Treguer D, Cui Y, Rouquier S, et al. MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis. J Neuroinflammation. 2024. https:\/\/doi.org\/10.1186\/s12974-024-03262-w.","journal-title":"J Neuroinflammation"},{"key":"1769_CR326","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1235222","author":"CD Moorman","year":"2023","unstructured":"Moorman CD, Yu S, Briseno CG, Phee H, Sahoo A, Ramrakhiani A, et al. CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1235222.","journal-title":"Front Immunol"},{"key":"1769_CR327","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj9331","author":"X Rui","year":"2024","unstructured":"Rui X, Alvarez Calderon F, Wobma H, Gerdemann U, Albanese A, Cagnin L, et al. <article-title update=\"added\">Human OX40L\u2013CAR-T regs target activated antigen-presenting cells and control T cell alloreactivity. Sci Transl Med. 2024. https:\/\/doi.org\/10.1126\/scitranslmed.adj9331.","journal-title":"Sci Transl Med"},{"issue":"7","key":"1769_CR328","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jgg.2022.05.005","volume":"49","author":"G Qu","year":"2022","unstructured":"Qu G, Chen J, Li Y, Yuan Y, Liang R, Li B. Current status and perspectives of regulatory T cell-based therapy. J Genet Genomics. 2022;49(7):599\u2013611. https:\/\/doi.org\/10.1016\/j.jgg.2022.05.005.","journal-title":"J Genet Genomics"},{"issue":"5","key":"1769_CR329","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/mt.2014.41","volume":"22","author":"D Blat","year":"2014","unstructured":"Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther. 2014;22(5):1018\u201328. https:\/\/doi.org\/10.1038\/mt.2014.41.","journal-title":"Mol Ther"},{"key":"1769_CR330","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytox.2020.100049","author":"JJ van Freen- Heeren","year":"2021","unstructured":"van Freen- Heeren JJ. Using CRISPR to enhance T cell effector function for therapeutic applications. Cytokine: X. 2021. https:\/\/doi.org\/10.1016\/j.cytox.2020.100049.","journal-title":"Cytokine: X"},{"key":"1769_CR331","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00633-8","author":"LV J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen LV, Christensen EB, Barnkob MB, Barington T. The clinical landscape of CAR NK cells. Exp Hematol Oncol. 2025. https:\/\/doi.org\/10.1186\/s40164-025-00633-8.","journal-title":"Exp Hematol Oncol"},{"key":"1769_CR332","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01083-5","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021. https:\/\/doi.org\/10.1186\/s13045-021-01083-5.","journal-title":"J Hematol Oncol"},{"key":"1769_CR333","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00998-9","author":"A Yilmaz","year":"2020","unstructured":"Yilmaz A, Cui H, Caligiuri MA, Yu J. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol. 2020. https:\/\/doi.org\/10.1186\/s13045-020-00998-9.","journal-title":"J Hematol Oncol"},{"key":"1769_CR334","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100003","author":"SD Reighard","year":"2020","unstructured":"Reighard SD, Cranert SA, Rangel KM, Ali A, Gyurova IE, de la Cruz-Lynch AT, et al. Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells. Cell Rep Med. 2020. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100003.","journal-title":"Cell Rep Med"},{"issue":"2","key":"1769_CR335","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/cei.12171","volume":"174","author":"LA Thurgood","year":"2013","unstructured":"Thurgood LA, Arentz G, Lindop R, Jackson MW, Whyte AF, Colella AD, et al. An immunodominant La\/SSB autoantibody proteome derives from public clonotypes. Clin Exp Immunol. 2013;174(2):237\u201344. https:\/\/doi.org\/10.1111\/cei.12171.","journal-title":"Clin Exp Immunol"},{"key":"1769_CR336","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clim.2018.04.006","volume":"192","author":"H Meng","year":"2018","unstructured":"Meng H, Sun X, Song Y, Zou J, An G, Jin Z, et al. La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease. Clin Immunol. 2018;192:40\u20139. https:\/\/doi.org\/10.1016\/j.clim.2018.04.006.","journal-title":"Clin Immunol"},{"key":"1769_CR337","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.01.004","author":"Y Chen","year":"2025","unstructured":"Chen Y, Xin Q, Zhu M, Qiu J, Luo Y, Li R, et al. Exploring CAR-macrophages in non-tumor diseases: therapeutic potential beyond cancer. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2025.01.004.","journal-title":"J Adv Res"},{"key":"1769_CR338","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00983-2","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian L, Dai X, Yu H, Wang J, Lei A, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020. https:\/\/doi.org\/10.1186\/s13045-020-00983-2.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1769_CR339","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s11010-024-05134-6","volume":"480","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Dai J, Liu T, Rao W, Li D, Gu Z, et al. Targeting cardiac fibrosis with chimeric antigen receptor-engineered cells. Mol Cell Biochem. 2024;480(4):2103\u201316. https:\/\/doi.org\/10.1007\/s11010-024-05134-6.","journal-title":"Mol Cell Biochem"},{"key":"1769_CR340","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202417831","author":"Z Liu","year":"2025","unstructured":"Liu Z, Chen C, Zhang Y, Ji F, Liu H, Du H, et al. Legumain in situ engineering promotes efferocytosis of CAR macrophage to treat cardiac fibrosis. Adv Mater. 2025. https:\/\/doi.org\/10.1002\/adma.202417831.","journal-title":"Adv Mater"},{"issue":"12","key":"1769_CR341","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/circresaha.124.325212","volume":"135","author":"J Wang","year":"2024","unstructured":"Wang J, Du H, Xie W, Bi J, Zhang H, Liu X, et al. CAR-macrophage therapy alleviates myocardial ischemia-reperfusion injury. Circ Res. 2024;135(12):1161\u201374. https:\/\/doi.org\/10.1161\/circresaha.124.325212.","journal-title":"Circ Res"},{"key":"1769_CR342","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202308377","author":"ST Chuang","year":"2024","unstructured":"Chuang ST, Stein JB, Nevins S, Kilic Bektas C, Choi HK, Ko WK, et al. Enhancing CAR macrophage efferocytosis via surface engineered lipid nanoparticles targeting LXR signaling. Adv Mater. 2024. https:\/\/doi.org\/10.1002\/adma.202308377.","journal-title":"Adv Mater"},{"key":"1769_CR343","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jconrel.2024.11.064","volume":"377","author":"F Du","year":"2025","unstructured":"Du F, Ye Z, He A, Yuan J, Su M, Jia Q, et al. An engineered \u03b11\u03b21 integrin-mediated Fc\u03b3RI signaling component to control enhanced CAR macrophage activation and phagocytosis. J Control Release. 2025;377:689\u2013703. https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.064.","journal-title":"J Control Release"},{"issue":"1","key":"1769_CR344","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2023","unstructured":"Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2023;25(1):102\u201316. https:\/\/doi.org\/10.1038\/s41590-023-01687-8.","journal-title":"Nat Immunol"},{"key":"1769_CR345","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01579-w","author":"P Sesques","year":"2024","unstructured":"Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, et al. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s13045-024-01579-w.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1769_CR346","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-23-0240","volume":"6","author":"F Luciani","year":"2025","unstructured":"Luciani F, Safavi A, Guruprasad P, Chen L, Ruella M. Advancing CAR T-cell therapies with artificial intelligence: opportunities and challenges. Blood Cancer Discov. 2025;OF1-OF4. https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0240.","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"1769_CR347","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","volume":"34","author":"L Ye","year":"2022","unstructured":"Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metabol. 2022;34(4):595\u2013e614514. https:\/\/doi.org\/10.1016\/j.cmet.2022.02.009.","journal-title":"Cell Metabol"},{"key":"1769_CR348","doi-asserted-by":"publisher","DOI":"10.3389\/fmmed.2023.1250508","author":"N B\u00e4ckel","year":"2023","unstructured":"B\u00e4ckel N, Hort S, Kis T, Nettleton DF, Egan JR, Jacobs JJL, et al. Elaborating the potential of artificial intelligence in automated CAR-T cell manufacturing. Front Mol Med. 2023. https:\/\/doi.org\/10.3389\/fmmed.2023.1250508.","journal-title":"Front Mol Med"},{"key":"1769_CR349","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.913287","author":"S Hort","year":"2022","unstructured":"Hort S, Herbst L, B\u00e4ckel N, Erkens F, Niessing B, Frye M, et al. Toward rapid, widely available autologous CAR-T cell therapy \u2013 artificial intelligence and automation enabling the smart manufacturing hospital. Front Med. 2022. https:\/\/doi.org\/10.3389\/fmed.2022.913287.","journal-title":"Front Med"},{"key":"1769_CR350","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1273507","author":"Z Wei","year":"2023","unstructured":"Wei Z, Xu J, Zhao C, Zhang M, Xu N, Kang L, et al. Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1273507.","journal-title":"Front Immunol"},{"key":"1769_CR351","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.03.023","author":"HS Ababneh","year":"2025","unstructured":"Ababneh HS, Ng AK, Wan J, Walburn T, Zhu L, Bobi\u0107 M, et al. 5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)\u2014Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed\/Refractory Large B Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2025. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1769_CR352","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2024.11.010","volume":"32","author":"M Logun","year":"2025","unstructured":"Logun M, Wang X, Sun Y, Bagley SJ, Li N, Desai A, et al. Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. Cell Stem Cell. 2025;32(2):181\u2013e190184. https:\/\/doi.org\/10.1016\/j.stem.2024.11.010.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"1769_CR353","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1038\/s41596-020-0402-9","volume":"15","author":"F Jacob","year":"2020","unstructured":"Jacob F, Ming G-l, Song H. Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing. Nat Protoc. 2020;15(12):4000\u201333. https:\/\/doi.org\/10.1038\/s41596-020-0402-9.","journal-title":"Nat Protoc"},{"key":"1769_CR354","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29647-0","author":"H Li","year":"2022","unstructured":"Li H, Harrison EB, Li H, Hirabayashi K, Chen J, Li Q-X, et al. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/s41467-022-29647-0.","journal-title":"Nat Commun"},{"key":"1769_CR355","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14070","author":"S Park","year":"2024","unstructured":"Park S, Laskow TC, Chen J, Guha P, Dawn B, Kim DH. Microphysiological systems for human aging research. Aging Cell. 2024. https:\/\/doi.org\/10.1111\/acel.14070.","journal-title":"Aging Cell"},{"issue":"7","key":"1769_CR356","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.stem.2024.04.018","volume":"31","author":"TI Maulana","year":"2024","unstructured":"Maulana TI, Teufel C, Cipriano M, Roosz J, Lazarevski L, van den Hil FE, et al. Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells. Cell Stem Cell. 2024;31(7):989\u2013e10021009. https:\/\/doi.org\/10.1016\/j.stem.2024.04.018.","journal-title":"Cell Stem Cell"},{"key":"1769_CR357","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2023.115247","author":"B Ma","year":"2023","unstructured":"Ma B, Liu X, Zhang Z, Ma C, Chand R, Patwardhan S. A digital nanoplasmonic microarray immunosensor for multiplexed cytokine monitoring during CAR T-cell therapy from a leukemia tumor microenvironment model. Biosens Bioelectron. 2023. https:\/\/doi.org\/10.1016\/j.bios.2023.115247.","journal-title":"Biosens Bioelectron"},{"key":"1769_CR358","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01492-8","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023. https:\/\/doi.org\/10.1186\/s13045-023-01492-8.","journal-title":"J Hematol Oncol"},{"key":"1769_CR359","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01164-5","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021. https:\/\/doi.org\/10.1186\/s13045-021-01164-5.","journal-title":"J Hematol Oncol"},{"key":"1769_CR360","doi-asserted-by":"publisher","unstructured":"Bensard CL, Wisidagama DR, Olson KA, Berg JA, Krah NM, Schell JC et al. Regulation of Tumor Initiation by the Mitochondrial Pyruvate Carrier. Cell Metab 2020; 31(2): 284\u2013300 e287. e-pub ahead of print 2019\/12\/10; https:\/\/doi.org\/10.1016\/j.cmet.2019.11.002","DOI":"10.1016\/j.cmet.2019.11.002"},{"issue":"1","key":"1769_CR361","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","volume":"20","author":"NM Chapman","year":"2019","unstructured":"Chapman NM, Boothby MR, Chi H. Metabolic coordination of T cell quiescence and activation. Nat Rev Immunol. 2019;20(1):55\u201370. https:\/\/doi.org\/10.1038\/s41577-019-0203-y.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1769_CR362","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52666-y","volume":"15","author":"JA Guerrero","year":"2024","unstructured":"Guerrero JA, Klysz DD, Chen Y, Malipatlolla M, Lone J, Fowler C, et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat Commun. 2024;15(1):8658. https:\/\/doi.org\/10.1038\/s41467-024-52666-y.","journal-title":"Nat Commun"},{"key":"1769_CR363","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010540","author":"W Hu","year":"2025","unstructured":"Hu W, Li F, Liang Y, Liu S, Wang S, Shen C. Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010540.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1769_CR364","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","volume":"32","author":"Y Shi","year":"2024","unstructured":"Shi Y, Kotchetkov IS, Dobrin A, Hanina SA, Rajasekhar VK, Healey JH, et al. GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Mol Ther. 2024;32(7):2393\u2013405. https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.006.","journal-title":"Mol Ther"},{"issue":"23","key":"1769_CR365","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1016\/j.cell.2024.08.029","volume":"187","author":"JG Baldwin","year":"2024","unstructured":"Baldwin JG, Heuser-Loy C, Saha T, Schelker RC, Slavkovic-Lukic D, Strieder N, et al. Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy. Cell. 2024;187(23):6614\u201330. https:\/\/doi.org\/10.1016\/j.cell.2024.08.029. e6621. e-pub ahead of print 2024\/09\/15.","journal-title":"Cell"},{"issue":"2","key":"1769_CR366","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101400","volume":"5","author":"Y Huang","year":"2024","unstructured":"Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024;5(2):101400. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101400.","journal-title":"Cell Rep Med"},{"key":"1769_CR367","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107487","author":"JJ Wilson","year":"2023","unstructured":"Wilson JJ, Wei J, Daamen AR, Sears JD, Bechtel E, Mayberry CL. Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment. iScience. 2023. https:\/\/doi.org\/10.1016\/j.isci.2023.107487.","journal-title":"iScience"},{"issue":"8","key":"1769_CR368","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41556-023-01180-2","volume":"25","author":"L Enkler","year":"2023","unstructured":"Enkler L, Szentgyorgyi V, Pennauer M, Prescianotto-Baschong C, Riezman I, Wiesyk A, et al. Arf1 coordinates fatty acid metabolism and mitochondrial homeostasis. Nat Cell Biol. 2023;25(8):1157\u201372. https:\/\/doi.org\/10.1038\/s41556-023-01180-2.","journal-title":"Nat Cell Biol"},{"key":"1769_CR369","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.101150","author":"H Liu","year":"2025","unstructured":"Liu H, Yang W, Jiang J. Targeting tumor metabolism to augment CD8\u2009+\u2009T cell anti-tumor immunity. J Pharm Anal. 2025. https:\/\/doi.org\/10.1016\/j.jpha.2024.101150.","journal-title":"J Pharm Anal"},{"key":"1769_CR370","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109911","author":"MI Matias","year":"2021","unstructured":"Matias MI, Yong CS, Foroushani A, Goldsmith C, Mongellaz C, Sezgin E. Regulatory T cell differentiation is controlled by \u03b1KG-induced alterations in mitochondrial metabolism and lipid homeostasis. Cell Rep. 2021. https:\/\/doi.org\/10.1016\/j.celrep.2021.109911.","journal-title":"Cell Rep"},{"issue":"6","key":"1769_CR371","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cmet.2025.04.008","volume":"37","author":"C Niu","year":"2025","unstructured":"Niu C, Wei H, Pan X, Wang Y, Song H, Li C, et al. Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming. Cell Metabol. 2025;37(6):1426\u2013e14411427. https:\/\/doi.org\/10.1016\/j.cmet.2025.04.008.","journal-title":"Cell Metabol"},{"key":"1769_CR372","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg3049","author":"J Li","year":"2023","unstructured":"Li J, Liu J, Zhou Z, Wu R, Chen X, Yu C. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023. https:\/\/doi.org\/10.1126\/scitranslmed.adg3049.","journal-title":"Sci Transl Med"},{"key":"1769_CR373","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101082","author":"Y Huang","year":"2024","unstructured":"Huang Y, Qin Y, He Y, Qiu D, Zheng Y, Wei J. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies. Drug Resist Updat. 2024. https:\/\/doi.org\/10.1016\/j.drup.2024.101082.","journal-title":"Drug Resist Updat"},{"issue":"6","key":"1769_CR374","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.ymthe.2025.01.035","volume":"33","author":"M Khalifeh","year":"2025","unstructured":"Khalifeh M, Salman H. Engineering resilient CAR T cells for immunosuppressive environment. Mol Ther. 2025;33(6):2391\u2013405. https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.035.","journal-title":"Mol Ther"},{"key":"1769_CR375","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01504-7","author":"Y Bulliard","year":"2023","unstructured":"Bulliard Y, Andersson BS, Baysal MA, Damiano J, Tsimberidou AM. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J Hematol Oncol. 2023. https:\/\/doi.org\/10.1186\/s13045-023-01504-7.","journal-title":"J Hematol Oncol"},{"key":"1769_CR376","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47799-z","author":"I Andreu-Saumell","year":"2024","unstructured":"Andreu-Saumell I, Rodriguez-Garcia A, M\u00fchlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsagu\u00e9 J. CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-47799-z.","journal-title":"Nat Commun"},{"key":"1769_CR377","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01452-1","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023. https:\/\/doi.org\/10.1038\/s41392-023-01452-1.","journal-title":"Signal Transduct Target Ther"},{"key":"1769_CR378","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01641-7","author":"M Pezzella","year":"2024","unstructured":"Pezzella M, Quintarelli C, Quadraccia MC, Sarcinelli A, Manni S, Iaffaldano L. Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. J Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s13045-024-01641-7.","journal-title":"J Hematol Oncol"},{"key":"1769_CR379","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba7308","author":"H Zhang","year":"2021","unstructured":"Zhang H, Li F, Cao J, Wang X, Cheng H, Qi K. A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.aba7308.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1769_CR380","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41589-021-00932-1","volume":"18","author":"TJ Gardner","year":"2021","unstructured":"Gardner TJ, Lee JP, Bourne CM, Wijewarnasuriya D, Kinarivala N, Kurtz KG, et al. Engineering CAR-T cells to activate small-molecule drugs in situ. Nat Chem Biol. 2021;18(2):216\u201325. https:\/\/doi.org\/10.1038\/s41589-021-00932-1.","journal-title":"Nat Chem Biol"},{"key":"1769_CR381","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02178-y","author":"J Nie","year":"2025","unstructured":"Nie J, Zhou L, Tian W, Liu X, Yang L, Yang X, et al. Deep insight into cytokine storm: from pathogenesis to treatment. Signal Transduct Target Ther. 2025. https:\/\/doi.org\/10.1038\/s41392-025-02178-y.","journal-title":"Signal Transduct Target Ther"},{"key":"1769_CR382","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01077-3","author":"J-Z Hou","year":"2021","unstructured":"Hou J-Z, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, et al. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol. 2021. https:\/\/doi.org\/10.1186\/s13045-021-01077-3.","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01769-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01769-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01769-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:06:00Z","timestamp":1767474360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-025-01769-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":382,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01769-0","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}